RNA Therapeutics USA : Pharmaceuticals : North America

<!DOCTYPE html > <html xmlns="http://www.w3.org/1999/xhtml"> <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="SKYPE_TOOLBAR" content="SKYPE_TOOLBAR_PARSER_COMPATIBLE" /><meta name="viewport" content="width=device-width, initial-scale=1" />  <script src="https://cdn-ukwest.onetrust.com/consent/2f42c8dd-6f0d-43ef-8823-35fceb025e84/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="2f42c8dd-6f0d-43ef-8823-35fceb025e84" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script>   <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-T3QT4FB');</script>   <script type="text/javascript" src="/_scripts/jquery.min.js"></script> <script type="text/javascript" src="/_scripts/bootstrap.min.js"></script> <script type="text/javascript" src="/_scripts/carouselTicker.min.js"></script> <script type="text/javascript" src="/_scripts/magnific-popup.js"></script> <script type="text/javascript" src="/_scripts/owl.carousel.min.js"></script> <script type="text/javascript" src="/_scripts/jquery.sidr.min.js"></script> <script type="text/javascript" src="/_scripts/jquery.validate.min.js"></script> <script type="text/javascript" src="/_scripts/additional-methods.min.js"></script> <script type="text/javascript" src="/_scripts/imagesloaded.pkgd.min.js"></script> <script type="text/javascript" src="/_scripts/popups/login.js?v=5"></script> <script type="text/javascript" src="/_scripts/popups/signup.js"></script> <script type="text/javascript" src="/_scripts/popups/speak.js"></script> <script type="text/javascript" src="/_scripts/popups/attend.js?v=1"></script> <script type="text/javascript" src="/_scripts/popups/sponsor.js"></script> <script type="text/javascript" src="/_scripts/popups/contact.js"></script> <script type="text/javascript" src="/_scripts/popups/gdpr.js?v=1"></script> <script type="text/javascript" src="/_scripts/popups/misc.js?v=4"></script> <script type="text/javascript" src="/_scripts/popups/downbroch.js?v=1"></script> <script type="text/javascript" src="/_scripts/new/ticker.js"></script> <script type="text/javascript" src="/_scripts/new/sliders.js?v=1"></script>  <script src="https://paypage-cdn.adflex.co.uk/MerchantLibrary/lib.min.js" type="text/javascript"></script> <script type="text/javascript" src="/_scripts/new/checkout.js?v=3"></script> <link href="/_styles/bootstrap.min.css" type="text/css" rel="stylesheet" /><link href="/_styles/jquery.sidr.dark.css" type="text/css" rel="stylesheet" /><link href="/_styles/magnific-popup.css" type="text/css" rel="stylesheet" /><link href="/_styles/owl.carousel.css" type="text/css" rel="stylesheet" /><link href="/_styles/style.css?v=6" type="text/css" rel="stylesheet" /> <script type="text/javascript" src="/_scripts/jquery.easing.js"></script> <script> $(document).ready(function () { $('.open-popup-link').magnificPopup({ type: 'inline', midClick: true // allow opening popup on middle mouse click. Always set it to true if you don't provide alternative source. }); }); </script> <title> RNA Therapeutics USA : Pharmaceuticals : North America </title> <link rel="canonical" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa" /> <script type="text/javascript"> $(window).scroll(function () { if ($(window).width() > 739) { var scroll = $(window).scrollTop(); if (scroll >= 600) { $(".mid_tab_banner").addClass("fixed2"); $(".mid_tab_sec").addClass("fixed2"); $(".daylist").addClass("fixed2"); } else { $(".mid_tab_banner").removeClass("fixed2"); $(".mid_tab_sec").removeClass("fixed2"); $(".daylist").removeClass("fixed2"); } } else { $(".mid_tab_banner").removeClass("fixed2"); $(".mid_tab_sec").removeClass("fixed2"); $(".daylist").removeClass("fixed2"); } }); function scrollToPosition(targetPos) { if (document.readyState === 'complete') { $('html, body').animate({ scrollTop: targetPos }, 100); } else { $(document).ready(function () { $('html, body').animate({ scrollTop: targetPos }, 100); }); } } $(document).ready(function () { var url = document.location.toString(); if (url.match('#')) { if (url.slice(-1) == "_") { url = url.substr(0, url.length - 1); } $('.nav-tabs a[href=#' + url.split('#')[1] + ']').tab('show'); } $('.nav-tabs a').on('shown.bs.tab', function (e) { window.location.hash = e.target.hash; window.scrollTo(0, 250); }) $('#DDNavigation li a,#btnDownloadCentre').click(function (e) { $('.nav-tabs a[href=' + $(this).attr('href') + ']').tab('show'); }) // Optimalisation: Store the references outside the event handler: var $window = $(window); function checkWidth() { var windowsize = $window.width(); if (url.match('#')) { if (url.split('#')[1] == "eventDetails") { if ( $(window).width() < 480) { window.scrollTo(0, 230); } } } } // Execute on load checkWidth(); // Bind event listener $(window).resize(checkWidth); }); $(window).ready(function () { $("#whySponsor-sponsor-overview-slider").owlCarousel({ items: 4, autoPlay: 3000, //Set AutoPlay to 3 seconds navSpeed: 600, navigation: true, navigationText: ["<", ">"], slideSpeed: 600, loop: true, center: true }); }); /* $(window).load(function () { var gdpr = getCookie("GDPRConsent"); $('#pop-GDPRConsent #GDPRConsent_eventid').text('6053') if (gdpr == "") { $.magnificPopup.open({ items: { src: '#pop-GDPRConsent' }, type: 'inline' }); } }); */ </script> <style> .columntext ul, .latestcontent ul { padding-left: 40px } .columntext li, .latestcontent li { list-style-type: disc; } </style> <meta property="og:title" content="RNA Therapeutics USA" /><meta property="og:image" content="https://www.smgconferences.com/eventImages/6053_overview.png?width=1036", /><meta property="og:description" content="SAE Media Group is proud to announce the 2nd annual RNA Therapeutics USA Conference taking place in Boston on the 23 – 24th October 2024" /><meta property="og:url" content="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa" /> <meta name="google-site-verification" content="QUxvzCpDXhln4QcLK-Z5Sp9QR04rGEFbCeiY9Jxm53k" /></head> <body>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-T3QT4FB" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <form method="post" action="./rna-usa" id="aspnetForm" style="height: 0;"> <div class="aspNetHidden"> <input type="hidden" name="ctl00_ToolkitScriptManager1_HiddenField" id="ctl00_ToolkitScriptManager1_HiddenField" value="" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__LASTFOCUS" id="__LASTFOCUS" value="" /> <input type="hidden" name="__VIEWSTATE1" id="__VIEWSTATE1" value="sgtlkqwy5vv0rzsv2psctxbh_252fe756-bf56-4dd8-a6fe-d0be3ae5f460" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['aspnetForm']; if (!theForm) { theForm = document.aspnetForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/WebForms.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ window.WebForm_PostBackOptions||document.write('<script type="text/javascript" src="/WebResource.axd?d=oZImrG5UtwhGQ2EFd2xYVfXxME8uqAgUJjvfYmUDuLNuZbTVjhVuiMfiJ9L2oLoXQXiM0aUb0aQ56yEdstw_TqT6ocb3Qsv7nTfVmIYw0FU1&t=638628243619783110"><\/script>');//]]> </script> <script type="text/javascript"> //<![CDATA[ var __cultureInfo = {"name":"en-GB","numberFormat":{"CurrencyDecimalDigits":2,"CurrencyDecimalSeparator":".","IsReadOnly":true,"CurrencyGroupSizes":[3],"NumberGroupSizes":[3],"PercentGroupSizes":[3],"CurrencyGroupSeparator":",","CurrencySymbol":"£","NaNSymbol":"NaN","CurrencyNegativePattern":1,"NumberNegativePattern":1,"PercentPositivePattern":1,"PercentNegativePattern":1,"NegativeInfinitySymbol":"-∞","NegativeSign":"-","NumberDecimalDigits":2,"NumberDecimalSeparator":".","NumberGroupSeparator":",","CurrencyPositivePattern":0,"PositiveInfinitySymbol":"∞","PositiveSign":"+","PercentDecimalDigits":2,"PercentDecimalSeparator":".","PercentGroupSeparator":",","PercentSymbol":"%","PerMilleSymbol":"‰","NativeDigits":["0","1","2","3","4","5","6","7","8","9"],"DigitSubstitution":1},"dateTimeFormat":{"AMDesignator":"AM","Calendar":{"MinSupportedDateTime":"\/Date(-62135596800000)\/","MaxSupportedDateTime":"\/Date(253402300799999)\/","AlgorithmType":1,"CalendarType":1,"Eras":[1],"TwoDigitYearMax":2049,"IsReadOnly":true},"DateSeparator":"/","FirstDayOfWeek":1,"CalendarWeekRule":2,"FullDateTimePattern":"dd MMMM yyyy HH:mm:ss","LongDatePattern":"dd MMMM yyyy","LongTimePattern":"HH:mm:ss","MonthDayPattern":"d MMMM","PMDesignator":"PM","RFC1123Pattern":"ddd, dd MMM yyyy HH\u0027:\u0027mm\u0027:\u0027ss \u0027GMT\u0027","ShortDatePattern":"dd/MM/yyyy","ShortTimePattern":"HH:mm","SortableDateTimePattern":"yyyy\u0027-\u0027MM\u0027-\u0027dd\u0027T\u0027HH\u0027:\u0027mm\u0027:\u0027ss","TimeSeparator":":","UniversalSortableDateTimePattern":"yyyy\u0027-\u0027MM\u0027-\u0027dd HH\u0027:\u0027mm\u0027:\u0027ss\u0027Z\u0027","YearMonthPattern":"MMMM yyyy","AbbreviatedDayNames":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"ShortestDayNames":["Su","Mo","Tu","We","Th","Fr","Sa"],"DayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"AbbreviatedMonthNames":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec",""],"MonthNames":["January","February","March","April","May","June","July","August","September","October","November","December",""],"IsReadOnly":true,"NativeCalendarName":"Gregorian Calendar","AbbreviatedMonthGenitiveNames":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec",""],"MonthGenitiveNames":["January","February","March","April","May","June","July","August","September","October","November","December",""]},"eras":[1,"A.D.",null,0]};//]]> </script> <script src="/ScriptResource.axd?d=khkmPYFAOU7d2Y-bUMUyQ_brWr3NNRtCccpO71ys36owLUDyjmN-SUgq3YC5ElMr8VL49txeNotB2cH9ZQXaPn5KqrHItjWM70XjglIJfQejPOxqIz8jatHA2SZt1HsO0&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys._Application && Sys.Observer)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=khkmPYFAOU7d2Y-bUMUyQ_brWr3NNRtCccpO71ys36owLUDyjmN-SUgq3YC5ElMr8VL49txeNotB2cH9ZQXaPn5KqrHItjWM70XjglIJfQejPOxqIz8jatHA2SZt1HsO0&t=ffffffffdd783992"><\/script>');//]]> </script> <script src="/ScriptResource.axd?d=kCGEEOkTaMA-ETUe9XtyMaoP2f9Ve0AMk8cO2dpfug3HRbMvbEACk2_P9aOGvBv0-5-ShQ3syc3FIHySKPiyhVmCHTNUTm4cRXeD8-RXStw2-nLeedpIfZaC97ueSZmmzBedTYno2aQ9jgw7f0ltKw2&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys.WebForms)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=kCGEEOkTaMA-ETUe9XtyMaoP2f9Ve0AMk8cO2dpfug3HRbMvbEACk2_P9aOGvBv0-5-ShQ3syc3FIHySKPiyhVmCHTNUTm4cRXeD8-RXStw2-nLeedpIfZaC97ueSZmmzBedTYno2aQ9jgw7f0ltKw2&t=ffffffffdd783992"><\/script>');//]]> </script> <script src="/ScriptResource.axd?d=iNKIkAPGpECD5JwIGUPvkUgkJsz8UySman5MYqbNmRiA8Zj6ANbOurMTmC_jp0xY1naCVrdGRAmBloCMQMrCKPqemnV06ELvTJEq_j5MRjlqLfJn9w4rytsd28ggnF2l9H194rxUDDno1aLGK738eZHgOCn139B2utTwMArGzT41&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys.Services)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=iNKIkAPGpECD5JwIGUPvkUgkJsz8UySman5MYqbNmRiA8Zj6ANbOurMTmC_jp0xY1naCVrdGRAmBloCMQMrCKPqemnV06ELvTJEq_j5MRjlqLfJn9w4rytsd28ggnF2l9H194rxUDDno1aLGK738eZHgOCn139B2utTwMArGzT41&t=ffffffffdd783992"><\/script>');Sys.Services._AuthenticationService.DefaultWebServicePath = '../../../Authentication_JSON_AppService.axd'; var PageMethods = function() { PageMethods.initializeBase(this); this._timeout = 0; this._userContext = null; this._succeeded = null; this._failed = null; } PageMethods.prototype = { _get_path:function() { var p = this.get_path(); if (p) return p; else return PageMethods._staticInstance.get_path();}, InitSession:function(succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'InitSession',false,{},succeededCallback,failedCallback,userContext); }, GetFirstname:function(succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'GetFirstname',false,{},succeededCallback,failedCallback,userContext); }, GetDialingCode:function(intCountryID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'GetDialingCode',false,{intCountryID:intCountryID},succeededCallback,failedCallback,userContext); }, RegisterAccount:function(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'RegisterAccount',false,{Username:Username,Password:Password,OptOut:OptOut,Title:Title,Surname:Surname,Firstname:Firstname,Organisation:Organisation,JobTitle:JobTitle,Phone:Phone,uid:uid,country:country},succeededCallback,failedCallback,userContext); }, SaveBasket:function(basket,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SaveBasket',false,{basket:basket},succeededCallback,failedCallback,userContext); }, ResetAccountPassword:function(Username,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ResetAccountPassword',false,{Username:Username},succeededCallback,failedCallback,userContext); }, ChangePassword:function(OldPassword,NewPassword,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ChangePassword',false,{OldPassword:OldPassword,NewPassword:NewPassword},succeededCallback,failedCallback,userContext); }, BrochureDownloadSignup:function(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'BrochureDownloadSignup',false,{intEventID:intEventID,strFirstName:strFirstName,strLastName:strLastName,strEmail:strEmail,strCompanyName:strCompanyName,strTelephoneNumber:strTelephoneNumber,blnReceiveInfo:blnReceiveInfo},succeededCallback,failedCallback,userContext); }, BrochureDownload:function(eventId,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'BrochureDownload',false,{eventId:eventId},succeededCallback,failedCallback,userContext); }, ComplementaryContentDownload:function(eventId,complementaryContentId,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ComplementaryContentDownload',false,{eventId:eventId,complementaryContentId:complementaryContentId},succeededCallback,failedCallback,userContext); }, ConferencePresentationDownload:function(intDownloadTypeID,intDownloadID,intEventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ConferencePresentationDownload',false,{intDownloadTypeID:intDownloadTypeID,intDownloadID:intDownloadID,intEventID:intEventID},succeededCallback,failedCallback,userContext); }, ProgrammeNotification:function(EventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ProgrammeNotification',false,{EventID:EventID},succeededCallback,failedCallback,userContext); }, ComplementaryContentDownloadNotification:function(EventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ComplementaryContentDownloadNotification',false,{EventID:EventID},succeededCallback,failedCallback,userContext); }, SetPaymentMethod:function(strEncryptedString,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SetPaymentMethod',false,{strEncryptedString:strEncryptedString},succeededCallback,failedCallback,userContext); }, ApplyVoucherCode:function(strWebVoucherCode,strOrderRef,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ApplyVoucherCode',false,{strWebVoucherCode:strWebVoucherCode,strOrderRef:strOrderRef},succeededCallback,failedCallback,userContext); }, SubmitSpeakerRequest:function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitSpeakerRequest',false,{eventId:eventId,notListedAbove:notListedAbove,howCanWeHelp:howCanWeHelp,organisation:organisation,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,topic:topic,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitAttendRequest:function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitAttendRequest',false,{eventId:eventId,notListedAbove:notListedAbove,howCanWeHelp:howCanWeHelp,organisation:organisation,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitSponsorRequest:function(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitSponsorRequest',false,{eventId:eventId,notListedAbove:notListedAbove,isSponsorLead:isSponsorLead,isSponsorSpeaking:isSponsorSpeaking,isSponsorExhibit:isSponsorExhibit,isSponsorNetworking:isSponsorNetworking,isSponsorCoffeeBreak:isSponsorCoffeeBreak,isSponsorLunch:isSponsorLunch,isSponsorBranding:isSponsorBranding,isSponsorLanyards:isSponsorLanyards,organisation:organisation,jobtitle:jobtitle,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,sponsorshipGoals:sponsorshipGoals,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitGDPRConsentRequest:function(eventId,email,giveConsent,name,phone,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitGDPRConsentRequest',false,{eventId:eventId,email:email,giveConsent:giveConsent,name:name,phone:phone},succeededCallback,failedCallback,userContext); }, SubmitGeneralRequest:function(name,jobTitle,org,phone,email,enquiry,enquiryType,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitGeneralRequest',false,{name:name,jobTitle:jobTitle,org:org,phone:phone,email:email,enquiry:enquiry,enquiryType:enquiryType},succeededCallback,failedCallback,userContext); }, AuthoriseToken:function(strToken,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'AuthoriseToken',false,{strToken:strToken},succeededCallback,failedCallback,userContext); }} PageMethods.registerClass('PageMethods',Sys.Net.WebServiceProxy); PageMethods._staticInstance = new PageMethods(); PageMethods.set_path = function(value) { PageMethods._staticInstance.set_path(value); } PageMethods.get_path = function() { return PageMethods._staticInstance.get_path(); } PageMethods.set_timeout = function(value) { PageMethods._staticInstance.set_timeout(value); } PageMethods.get_timeout = function() { return PageMethods._staticInstance.get_timeout(); } PageMethods.set_defaultUserContext = function(value) { PageMethods._staticInstance.set_defaultUserContext(value); } PageMethods.get_defaultUserContext = function() { return PageMethods._staticInstance.get_defaultUserContext(); } PageMethods.set_defaultSucceededCallback = function(value) { PageMethods._staticInstance.set_defaultSucceededCallback(value); } PageMethods.get_defaultSucceededCallback = function() { return PageMethods._staticInstance.get_defaultSucceededCallback(); } PageMethods.set_defaultFailedCallback = function(value) { PageMethods._staticInstance.set_defaultFailedCallback(value); } PageMethods.get_defaultFailedCallback = function() { return PageMethods._staticInstance.get_defaultFailedCallback(); } PageMethods.set_enableJsonp = function(value) { PageMethods._staticInstance.set_enableJsonp(value); } PageMethods.get_enableJsonp = function() { return PageMethods._staticInstance.get_enableJsonp(); } PageMethods.set_jsonpCallbackParameter = function(value) { PageMethods._staticInstance.set_jsonpCallbackParameter(value); } PageMethods.get_jsonpCallbackParameter = function() { return PageMethods._staticInstance.get_jsonpCallbackParameter(); } PageMethods.set_path("rna-usa"); PageMethods.InitSession= function(onSuccess,onFailed,userContext) {PageMethods._staticInstance.InitSession(onSuccess,onFailed,userContext); } PageMethods.GetFirstname= function(onSuccess,onFailed,userContext) {PageMethods._staticInstance.GetFirstname(onSuccess,onFailed,userContext); } PageMethods.GetDialingCode= function(intCountryID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.GetDialingCode(intCountryID,onSuccess,onFailed,userContext); } PageMethods.RegisterAccount= function(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,onSuccess,onFailed,userContext) {PageMethods._staticInstance.RegisterAccount(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,onSuccess,onFailed,userContext); } PageMethods.SaveBasket= function(basket,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SaveBasket(basket,onSuccess,onFailed,userContext); } PageMethods.ResetAccountPassword= function(Username,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ResetAccountPassword(Username,onSuccess,onFailed,userContext); } PageMethods.ChangePassword= function(OldPassword,NewPassword,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ChangePassword(OldPassword,NewPassword,onSuccess,onFailed,userContext); } PageMethods.BrochureDownloadSignup= function(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,onSuccess,onFailed,userContext) {PageMethods._staticInstance.BrochureDownloadSignup(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,onSuccess,onFailed,userContext); } PageMethods.BrochureDownload= function(eventId,onSuccess,onFailed,userContext) {PageMethods._staticInstance.BrochureDownload(eventId,onSuccess,onFailed,userContext); } PageMethods.ComplementaryContentDownload= function(eventId,complementaryContentId,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ComplementaryContentDownload(eventId,complementaryContentId,onSuccess,onFailed,userContext); } PageMethods.ConferencePresentationDownload= function(intDownloadTypeID,intDownloadID,intEventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ConferencePresentationDownload(intDownloadTypeID,intDownloadID,intEventID,onSuccess,onFailed,userContext); } PageMethods.ProgrammeNotification= function(EventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ProgrammeNotification(EventID,onSuccess,onFailed,userContext); } PageMethods.ComplementaryContentDownloadNotification= function(EventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ComplementaryContentDownloadNotification(EventID,onSuccess,onFailed,userContext); } PageMethods.SetPaymentMethod= function(strEncryptedString,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SetPaymentMethod(strEncryptedString,onSuccess,onFailed,userContext); } PageMethods.ApplyVoucherCode= function(strWebVoucherCode,strOrderRef,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ApplyVoucherCode(strWebVoucherCode,strOrderRef,onSuccess,onFailed,userContext); } PageMethods.SubmitSpeakerRequest= function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitSpeakerRequest(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitAttendRequest= function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitAttendRequest(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitSponsorRequest= function(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitSponsorRequest(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitGDPRConsentRequest= function(eventId,email,giveConsent,name,phone,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitGDPRConsentRequest(eventId,email,giveConsent,name,phone,onSuccess,onFailed,userContext); } PageMethods.SubmitGeneralRequest= function(name,jobTitle,org,phone,email,enquiry,enquiryType,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitGeneralRequest(name,jobTitle,org,phone,email,enquiry,enquiryType,onSuccess,onFailed,userContext); } PageMethods.AuthoriseToken= function(strToken,onSuccess,onFailed,userContext) {PageMethods._staticInstance.AuthoriseToken(strToken,onSuccess,onFailed,userContext); } var gtc = Sys.Net.WebServiceProxy._generateTypedConstructor; if (typeof(BasketItems) === 'undefined') { var BasketItems=gtc("BasketItems"); BasketItems.registerClass('BasketItems'); } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAASvVXD1oYELeveMr0vHCmYPVi0kMSdTVUTG1voF0fiHcgpO3MFqIPLeyEaVVEMlwUvLjtxrnzfA0pRyMpqEAoQYN3BleO/Qw1FLF2nV9gHb2vx+Sb/n1nfsQ3vvU0HDxJ8=" /> </div> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$ToolkitScriptManager1', 'aspnetForm', [], [], [], 90, 'ctl00'); //]]> </script> <div class="container-fluid"> <header class="container"> <div class="col-md-3"> <a href="/Default.aspx"><img alt="Home" src="/_images/newsite/logo.png" /></a> </div> <div class="col-md-9"> <div class="participate"> <a href="/about-us/life-at-saemedia/">About Us</a> <a href="/privacy-legals/privacy-policy/">Privacy Policy</a> <a href="/privacy-legals/code-of-conduct/">Conduct</a> <a href="#pop-speak" class="open-popup-link">Speak</a> <a href="#pop-sponsor" class="open-popup-link">Sponsor</a> <a href="#pop-attend" class="open-popup-link">Attend</a> <span id="menu_signup_login" style=""> <a href="#pop-login" class="open-popup-link">Sign up / Login</a><a href="#pop-login" class="open-popup-link linkedin hidden" ></a> </span> <span id="menu_logout" style="display:none"> <a href="javascript:void(0)">Sign out</a> </span> </div> <div class="telmail text-right"> <span> <a href="#pop-contact" class="open-popup-link ">+44 (0)20 7827 6000</a> <a href="#pop-contact" class="open-popup-link">events@saemediagroup.com</a></span> </div> <div class="cart"> <a href="/checkout"><span><img src="/_images/newsite/shopping-cart-16.png" alt="cart" /> Basket Total: £0.00</span></a> </div> </div> </header> </div>  <nav class="navbar navbar-default container-fluid red main-nav"> <div class="container"> <div class="navbar-header"> <button type="button" class="navbar-toggle " id="simple-menu" data-target="#sidr"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div>  <div id="sidr" class="hidden">  <div class="navbar-header pus-menu"> <button type="button" class="navbar-toggle" id="simple-menu2" data-target="#sidr" > <span class="sr-only">Toggle navigation</span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div> <ul> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> <li><a href="/about-us/life-at-saemedia/">About Us</a></li> <li><a href="/privacy-legals/privacy-policy/">Privacy Policy</a></li> <li><a href="/privacy-legals/code-of-conduct/">Conduct</a></li> <li><a href="#pop-speak" class="open-popup-link">Speak</a></li> <li><a href="#pop-sponsor" class="open-popup-link">Sponsor</a></li> <li><a href="#pop-attend" class="open-popup-link">Attend</a></li> <li><a href="/about-us/help">Help</a></li> </ul> </div> <script> $(document).ready(function () { $('#simple-menu').sidr('open'); $('#simple-menu2').sidr('close'); $('#sidr').removeClass('hidden'); }); </script> <div class="collapse navbar-collapse" id="main-nav"> <ul class="nav navbar-nav"> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> </ul> </div> <div class="search" style="display:none;"> <input name="ctl00$midMenuMain$search1$TextBoxSearch" type="text" maxlength="32" onchange="javascript:setTimeout('__doPostBack(\'ctl00$midMenuMain$search1$TextBoxSearch\',\'\')', 0)" onkeypress="if (WebForm_TextBoxKeyHandler(event) == false) return false;" id="ctl00_midMenuMain_search1_TextBoxSearch" /> <a href="#pop-cpd" class="open-popup-link"><img src="/_images/newsite/cpd.png" alt="" class="cpdimg"/></a> </div> </div> </nav> <input type="hidden" name="ctl00$MainContent$eventID" id="ctl00_MainContent_eventID" value="6053" /> <input type="hidden" name="ctl00$MainContent$peventID" id="ctl00_MainContent_peventID" value="6086" /> <div class="container-fluid darkgrey hidden"> <div class="container carouselTicker"> <ul class="newsticker"> </ul> </div> </div> <div class="image-bg-fluid-height banner" id="intro" style="background: url('https://www.smgconferences.com/_images/eventBanners/6053.png') no-repeat 0 0; background-size: cover; "> <div class="container" style="position:relative; min-height:inherit;"> <div class="dropdown" id="DDNavigation"> <button class="btn btn-default dropdown-toggle" type="button" id="dropdownMenu1" data-toggle="dropdown" aria-expanded="true"> Navigation <span class="caret"></span> </button> <ul class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu1"> <li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_overview">Overview</a></li> <li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_programme">Agenda</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_speakers">Speakers</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_sponsors">Sponsors</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_partners">Partners</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_associatedevents">Associated Events</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_venue">Venue</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_downloads">Content</a></li> </ul> </div> <div class="banner-content"> <h1 style="color:#fff;">RNA Therapeutics USA</h1> <h3 class="pink-header" style="color:#fff;"> October 23 - October 24, 2024 <br /> USA<br /> </h3> <p style="color:#fff;">BOLSTERING THE LATEST ADVANCES AND OPPORTUNITIES IN RNA-BASED MEDICINE</p> <div class="col-xs-12 bottomAlignButtons"> <div class="col-sm-6" style="padding: 0;"> <ul class="button_list"> <li><a href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa/booknow" target="" class="button-blue">Buy Conference Papers</a></li> </ul>  </div>  </div> </div> </div> </div> <div class="mid_tab_sec mid_tab_sec_edit"> <div class="container"> <div class="row"> <div class="col-sm-12"> <div class="mid_tab_Inner"> <div class="mid_top"> <div class="mid_tab_banner /*image-bg-fluid-height banner*/" style="background: url('https://www.smgconferences.com/_images/eventBanners/6053.png?height=50&width=1140&mode=crop') no-repeat 0 0;"> <div style="font:700 20px/24px Montserrat; color:#fff; padding-left: 5px; padding-top: 4px;">RNA Therapeutics USA</div> <div style="font:500 16px/18px Montserrat; color:#fff; padding-left: 5px; ">October 23 - October 24, 2024</div> </div> <ul class="nav nav-tabs mid_tab mid_tab_edit" role="tablist">  <li role="presentation"><a href="#tab_overview" aria-controls="tab_new1" role="tab" data-toggle="tab">Overview</a></li> <li id="ctl00_MainContent_liProgramme" role="presentation"><a href="#tab_programme" aria-controls="tab_programme" role="tab" data-toggle="tab">Agenda</a></li> <li id="ctl00_MainContent_liSpeakers" role="presentation"><a href="#tab_speakers" aria-controls="tab_speakers" role="tab" data-toggle="tab">Speakers</a></li> <li id="ctl00_MainContent_liSponsors" role="presentation"><a href="#tab_sponsors" aria-controls="tab_sponsors" role="tab" data-toggle="tab">Sponsors</a></li> <li id="ctl00_MainContent_liPartners" role="presentation"><a href="#tab_partners" aria-controls="tab_partners" role="tab" data-toggle="tab">Partners</a></li> <li id="ctl00_MainContent_liAssociatedEvents" role="presentation"><a href="#tab_associatedevents" aria-controls="tab_associatedevents" role="tab" data-toggle="tab">Associated Events</a></li> <li id="ctl00_MainContent_liVenue" role="presentation"><a href="#tab_venue" aria-controls="tab_venue" role="tab" data-toggle="tab">Venue</a></li> <li id="ctl00_MainContent_liDownload" role="presentation"><a href="#tab_downloads" aria-controls="tab_downloads" role="tab" data-toggle="tab">Content</a></li> </ul> <div class="sponcer_event2 sponcer_event_edit" style="float:right"> <ul> <li><a href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=db&dl=br&p1=6053">Download Brochure</a></li> <li><a href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa/booknow" target="" class="actv">Register To Attend</a></li> </ul> </div> </div> </div> </div> </div> </div> </div>  <div class="tab_main"> <div class="container"> <div class="row"> <div class="col-sm-12"> <div class="tab-content"> <div role="tabpanel" class="tab-pane active" id="tab_overview"> <div class="overview"> <div class="row"> <div class="col-md-6"> <div class="overview_pic"> <img id="ctl00_MainContent_ctl02_imgOverviewImage" src="/eventImages/6053_overview.png?width=1036" alt="RNA Therapeutics USA" /> </div> <div class="col-sm-12" style="margin-top:20px;"> <div class="sharethis "> <div class="share"> <p class="pink-header" style="text-align: left;">follow us</p> <a id="ctl00_MainContent_ctl02_hypLinkedIn" class="addthis_button_linkedin linkedin" href="https://www.linkedin.com/company/saemediagrouppharma/" target="_blank"> <img src="/_images/newsite/In-2C-48px-R.png" border="0" alt="Follow us on LinkedIn" /> </a> <a id="ctl00_MainContent_ctl02_hypTwitter" class="addthis_button_twitter twitter" href="https://x.com/saemgpharma" target="_blank"> <img src="/_images/newsite/x-logo-black.png" border="0" alt="Follow us on X" /> </a> </div> </div> </div> </div> <div class="col-md-6"> <div style="background-color: #fff;border: none;border-bottom: 1px solid #000;padding: 0;"> <h4 class="panel-title"> <a data-toggle="collapse" data-parent="#accordion" href="#collapseOne" aria-expanded="true" aria-controls="collapseOne">Conference Overview </a> </h4> </div> <div class="panel-body" id="divOverview"> <p><strong>JUST ANNOUNCED: END OF DAY 1 NETWORKING DRINKS RECEPTION</strong></p> <p>This year, for the first time ever, RNA Therapeutics is in association with AI in Drug Discovery USA to create<strong> Drug Discovery Week.</strong> From October 21-25, 2024, as part of SAE Media Group’s renowned series of conferences, we will unite top experts from major pharma and biotech companies to network and share insights, advancing the development and application of RNA Therapeutics and AI solutions.</p> <p><br /> Explore the latest advances in RNA therapeutics, analytical and control processes, and vaccine development. Gain access to cutting-edge innovations in delivery technologies for precision targeting, with case studies on LNPs and more. Discover how AI can optimize drug discovery and delivery platforms, as well as formulation strategies to enhance therapeutic success.</p> <p><br /> <strong>Special offer! </strong>Purchase both an RNA Therapeutics USA ticket and an AI USA pass to receive 50% off both purchases. Book your tickets here—simply fill out our short form, and a team member will contact you to discuss your needs. Please note: this offer is for new bookings only and cannot be used in conjunction with other offers.<br />  </p> </div> </div> </div> </div> <div id="speakers"> <h2>FEATURED SPEAKERS</h2> <div id="keynote-slider"> <div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223867.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Derek O Hagan" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Derek O Hagan</a></h3> <div class="speaker-details">Senior Advisor R&D, GSK</div> <div class="speaker-profile hidden"><p>I am currently a Senior Advisor in GSK Vaccines R&D. Prior to my current role I was the Global Head of Discovery Support and New Technology in GSK. Previously, I was VP, Global Head of Vaccine Chemistry and Formulation for Novartis Vaccines. I have extensive experience on Vaccine Adjuvants, including R&D on several included in licensed products, and I was a member of the Team that initiated work on RNA vaccines in Novartis in 2009. I am a Fellow of the American Association of Pharmaceutical Scientists. I was previously awarded the Conference Science medal of the Royal Pharmaceutical Society of Great Britain, and the Young Investigator Research Achievement Award of the Controlled Release Society. I was named as the ‘most inventive scientist’ in Chiron Corp, Emeryville.</p> <ul> <li>175 peer reviewed publications (h-index 105, Google Scholar)</li> <li>Named inventor on >70+ patents<br />  </li> </ul></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223856.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Hetal Patel" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Hetal Patel</a></h3> <div class="speaker-details">Senior Principle Scientist/Group Leader, Pfizer</div> <div class="speaker-profile hidden"><p>I am a group leader/Senior Principal Scientist at Pfizer Analytical Research and Development managing early and late-stage method validation and transfers. <br /> I have a masters in organic chemistry, Ph.D. in protein chemistry/biochemistry from Rutgers University and Postdoctoral from Albert Einstein, NY. I pursued MBA in management from Babson (finance, leadership excellence, people management) during my tenure at Pfizer. <br /> I have hands on experience working with mAbs, mRNA, small molecules, including small molecule synthesis, protein expression, variety of chromatographic/spectroscopic techniques, biochemical and biophysical characterization technologies, GMP inspections/audits, regulatory submissions/query responses. Lately, I have been actively leading implementation of ICH Q2 (R2) and ICH Q14 approaches around using prior knowledge and abbreviated validations in late-stage mRNA and mAb product development.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Jason Zhang" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Jason Zhang</a></h3> <div class="speaker-details">Co-Founder and CEO, Zipcode Bio</div> <div class="speaker-profile hidden"><p>Dr. Jason Zhang is the Co-Founder and CEO of Zipcode Bio, a leading biotechnology company developing next-generation nucleic acid-based medicines. Before founding Zipcode Bio, he was CSO at two biotech firms, overseeing preclinical R&D and pipeline strategy. Dr. Zhang has broad expertise in oncology, immunology, neurology, and infectious diseases, working with therapeutic modalities like mRNA, AAV, antibodies, and oligonucleotides.<br /> He has successfully advanced multiple drug candidates through clinical trials and contributed to a marketed drug. Dr. Zhang also brings extensive experience in business development and alliance management. He holds dual PhDs in Immunology (NYU) and Chemistry (Peking Union Medical College), and completed postdoctoral training at Yale and Harvard, as well as a CEO program at Haas School of Business.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223860.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Jay Sarkar" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Jay Sarkar</a></h3> <div class="speaker-details">Researcher and Entrepreneur, Stanford University</div> <div class="speaker-profile hidden"><p>Dr. Sarkar is a researcher and entrepreneur with a background in applied physics and electrical engineering, which he utilizes to develop systems biology solutions for medicine. He built his first company off his foundational PhD work at Stanford University, where he pioneered the use the mRNA modality for transiently reprogramming cell epigenetics to specifically reset cellular age. The approach has grown as one of the hottest in the longevity community, with some of the largest startup investments in biotech history. He has now progressed to studying the broader problem of new modality integration and distribution in a variety of tissues.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/225754.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Kevin Kim" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Kevin Kim</a></h3> <div class="speaker-details">VP, Discovery, miRecule, Inc.</div> <div class="speaker-profile hidden"><p>Kevin is an experienced leader in RNA therapeutic discovery with a track record of successfully managing research organizations and executing multiple pipeline programs to overcome technical and developmental challenges to bring RNA therapies to the clinic for genetic disorders.<br /> Kevin received his doctoral degree at UCLA and worked with the world-renowned experts on neuromuscular diseases, Dr. Lee Rubin at Harvard University and Dr. Robert Baloh at Cedars- Sinai Hospital, to unravel the disease mechanisms and potential therapeutic pathways for devastating diseases such as ALS and CMT. Over a decade of experience in academia and in various industry settings (start-up, biotech and pharma) has culminated in multiple academic publications and patents as well as contribution to the development of the next generation stereopure ASO drugs for CNS diseases (Wave Life Sciences) and cardioprotective therapeutic (Stem Cell Theranostics) which are currently undergoing preclinical and clinical evaluations. As Senior Director of Discovery Biology at Sarepta Therapeutics, Kevin and his team enhanced the delivery of FDA-approved PMO platform and expanded the utility of the platform to discover novel RNA therapeutics for genetic diseases. Kevin is currently serving as VP of Discovery at miRecule, Inc.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223861.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Kinkini Roy" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Kinkini Roy</a></h3> <div class="speaker-details">Associate Director, Aviceda Therapeutics</div> <div class="speaker-profile hidden"><p>After finishing PhD and postdoc study from University of Massachusetts Amherst, Kinkini Roy worked in industry for last 12 years in Boston Biotech as well as big corporation. Currently she is leading the program for the next-generation RNA therapeutics using a proprietary synthetic, high-affinity, multi-valent glycans that target extrahepatic cells and improve intracellular delivery and efficacy of siRNA, Anti- sense oligonucleotides, mRNA-based therapeutics, Crispr-Cas9 gene editing and lysosomal targeted protein degradation. Along with that she is leading the formulation development team and develop the formulation development strategy for pipeline development.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223857.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Martin Akerman" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Martin Akerman</a></h3> <div class="speaker-details">CTO & Co-Founder, Envisagenics</div> <div class="speaker-profile hidden"><p>Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/225239.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Pushkar Saralkar" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Pushkar Saralkar</a></h3> <div class="speaker-details">Senior Scientist, Pfizer</div> <div class="speaker-profile hidden"><p>Pushkar Saralkar is a Senior Scientist at Pfizer within the BioTherapeutics Pharmaceutical Research & Development organization in Andover, MA. Dr Saralkar is experienced in drug product development, with a particular interest in mRNA lipid nanoparticles. His research is broadly focused on developing delivery solutions to advance novel therapeutics into the clinic and is driven by developing breakthroughs that can change patient's lives.</p> <p>Dr Saralkar completed a Ph.D. (Pharmaceutical Science) in 2021 at West Virginia University with focus in nanoparticle-based drug delivery, CNS targeting and BBB pharmacokinetics. His research targeted mitochondrial protein mitoNEET to improve tissue survival following cerebral ischemia and reperfusion injury.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223723.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Richard Geary" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Richard Geary</a></h3> <div class="speaker-details">EVP, Chief Development Officer, Ionis Pharmaceuticals, Inc.</div> <div class="speaker-profile hidden"><p>Dr. Geary is the Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 50 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led six successful antisense medicine development programs through approvals in multiple jurisdictions.<br /> During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts. <br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/224684.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Sandy Hinckley" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Sandy Hinckley</a></h3> <div class="speaker-details">VP, Head of Discovery, QurAlis Corporation</div> <div class="speaker-profile hidden"><p>Sandy Hinckley, Ph.D., is an accomplished drug-discovery scientist with a background as a human stem cell biologist and neuroscientist, focusing on disease modeling, therapeutic discovery, and translational research. Dr. Hinckley is currently vice president, head of discovery at QurAlis Corporation, a biotech company at the forefront of discovering and developing transformative precision medicines for neurodegenerative diseases, where she leads QurAlis' drug discovery efforts and biomarker strategies. She has worked at QurAlis since 2018, bringing forward two programs into clinical studies, including QRL-201, a splice-switching oligonucleotide for restoring STATHMIN-2 in sporadic ALS and other neurodegenerative diseases.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223858.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Sourav Choudhury" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Sourav Choudhury</a></h3> <div class="speaker-details">Head AAV Technologies, Sanofi</div> <div class="speaker-profile hidden"><p>Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.<br /> Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223868.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Steve Pascolo" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Steve Pascolo</a></h3> <div class="speaker-details">Founder and CEO, Miescher Pharma GmbH</div> <div class="speaker-profile hidden"><p>Trained as an immunologist at the Pasteur Institute (Paris, France), Prof. Steve Pascolo started working on mRNA vaccine in 1998 in Tuebingen, Germany. In 2000, he co-founded CureVac and was Chief Scientific Officer (CSO) of the company, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he left CureVac and continued the development of immunotherapies based on RNA at the University Hospital of Zurich. In 2008, he founded Miescher Pharma to support this work. In 2017, Prof. Pascolo implemented in the University of Zurich an academic mRNA platform. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Sudhir Agrawal" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Sudhir Agrawal</a></h3> <div class="speaker-details">Founder and President, ARNAY Sciences</div> <div class="speaker-profile hidden"><p>Sudhir Agrawal, D. Phil., FRSC, is the founder and President of ARNAY Sciences. He also serves as an Affiliate Professor in the Department of Medicine at UMass Chan Medical School. Over the last three decades, his research interest has been discovering and developing RNA therapeutics, including antisense and immunotherapy. He focuses on the chemical biology of nucleic acids for creating RNA therapeutics. He has published over 300 research papers and is listed as a co-inventor of more than 500 patents worldwide. He has edited four books on oligonucleotides and antisense technology, including a recent book on ‘Advances in Nucleic Acid Therapeutics’ by The Royal Society of Chemistry. He is currently serving as a member of the scientific advisory board of several biotechnology companies.</p> <p>He obtained his D.Phil. in Chemistry from Allahabad University in India and conducted postdoctoral research at MRC’s Laboratory of Molecular Biology, Cambridge, UK. His research in the antisense field started in Paul Zamecnik’s laboratory at the Worcester Foundation of Experimental Biology, now UMass Chan Medical School. He was a co-founder of Idera Pharmaceuticals and held various roles until 2017.</p> <p>In 2022, the Oligonucleotide Therapeutic Society awarded him the Lifetime Achievement Award.</p> <p> </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223864.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Yue Hui" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Yue Hui</a></h3> <div class="speaker-details">Scientist, Moderna</div> <div class="speaker-profile hidden"><p>I earned my Ph.D. degree in Chemical Engineering from Caltech under Professor David A. Tirrell. In September 2022, I joined Moderna as a Scientist in Formulation Discovery. Here, I lead research initiatives focused on LNP process fundamentals and innovation, as well as novel LNP systems for both hepatic and extra-hepatic delivery of nucleic acids.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/224685.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Zdravka Medarova" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Zdravka Medarova</a></h3> <div class="speaker-details">Chief Scientific Officer, TransCode Therapeutics</div> <div class="speaker-profile hidden"><p>Zdravka Medarova, PhD has served as Scientific Co-Founder and a member of the advisory board of TransCode since January 2016. Dr.<br /> Medarova has been on the Faculty of Harvard Medical School and MGH since June 2007. She has served as an Associate Professor of Radiology at Harvard Medical School from April 2016 and as an Assistant in Neuroimaging at the Athinoula A. Martinos Center for Biomedical Imaging at MGH since June 2007. Dr. Medarova joined TransCode fulltime as the Chief Technology Officer on October 1, 2021. Dr. Medarova is a geneticist/cancer biologist by training and is internationally recognized for her work on non-coding RNA for cancer therapy. She is one of the first to describe the design and application of nanoparticles as carriers of siRNA to tumors. Since then, her research has focused on developing nanotechnology and imaging tools to better understand cancer initiation and progression and applying this knowledge to design clinically relevant therapeutic and diagnostic agents against cancer. Dr. Medarova obtained a B.A. in pre-medicine from the University of Southern Maine in September 1998 and a Ph.D. in Genetics from the University of New Hampshire in December 2002.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/223859.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Zimeng Wang" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Zimeng Wang</a></h3> <div class="speaker-details">Senior Scientist, AstraZeneca</div> <div class="speaker-profile hidden"><p>Zimeng is a senior scientist of Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca. His research in AZ includes formulation optimization to enhance the efficacy and safety of LNP vaccines, development of dry powder LNPs to improve RT stability, and development of LNPs for local/targeted delivery. Before joining AZ, he worked in Phosphorex Inc. on development of sustained release microspheres and targeted delivery nanoparticles. Zimeng got his PhD in University of Rhode Island focusing on development of dry powder aerosol nanocomposite microparticles for the treatment of pulmonary diseases.</p></div></div></div> </div> <script> $(window).ready(function () { $("#keynote-slider").owlCarousel({ //autoPlay: 3000, //Set AutoPlay to 3 seconds slideSpeed: 600, pagination: false, navigation: true, navigationText: ["<", ">"], stopOnHover: true, items: 4, itemsDesktop: [1199, 3], itemsDesktopSmall: [979, 3], center: true, loop: true }); }); </script> <div class="row"> <div class="col-md-12 sponsors marg2"> <div class="buttons"> <a id="hlAll" href="#pop-speakers-all" class="open-popup-link button-white">view all speakers</a> </div> </div> </div> <div id="pop-speakers-all" class="white-popup mfp-hide"> <br> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Derek O Hagan</h3> Senior Advisor R&D, GSK </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl01_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223867.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Derek O Hagan" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>I am currently a Senior Advisor in GSK Vaccines R&D. Prior to my current role I was the Global Head of Discovery Support and New Technology in GSK. Previously, I was VP, Global Head of Vaccine Chemistry and Formulation for Novartis Vaccines. I have extensive experience on Vaccine Adjuvants, including R&D on several included in licensed products, and I was a member of the Team that initiated work on RNA vaccines in Novartis in 2009. I am a Fellow of the American Association of Pharmaceutical Scientists. I was previously awarded the Conference Science medal of the Royal Pharmaceutical Society of Great Britain, and the Young Investigator Research Achievement Award of the Controlled Release Society. I was named as the ‘most inventive scientist’ in Chiron Corp, Emeryville.</p> <ul> <li>175 peer reviewed publications (h-index 105, Google Scholar)</li> <li>Named inventor on >70+ patents<br />  </li> </ul> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Hetal Patel</h3> Senior Principle Scientist/Group Leader, Pfizer </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl02_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223856.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Hetal Patel" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>I am a group leader/Senior Principal Scientist at Pfizer Analytical Research and Development managing early and late-stage method validation and transfers. <br /> I have a masters in organic chemistry, Ph.D. in protein chemistry/biochemistry from Rutgers University and Postdoctoral from Albert Einstein, NY. I pursued MBA in management from Babson (finance, leadership excellence, people management) during my tenure at Pfizer. <br /> I have hands on experience working with mAbs, mRNA, small molecules, including small molecule synthesis, protein expression, variety of chromatographic/spectroscopic techniques, biochemical and biophysical characterization technologies, GMP inspections/audits, regulatory submissions/query responses. Lately, I have been actively leading implementation of ICH Q2 (R2) and ICH Q14 approaches around using prior knowledge and abbreviated validations in late-stage mRNA and mAb product development.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Jason Zhang</h3> Co-Founder and CEO, Zipcode Bio </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl03_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Jason Zhang" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Jason Zhang is the Co-Founder and CEO of Zipcode Bio, a leading biotechnology company developing next-generation nucleic acid-based medicines. Before founding Zipcode Bio, he was CSO at two biotech firms, overseeing preclinical R&D and pipeline strategy. Dr. Zhang has broad expertise in oncology, immunology, neurology, and infectious diseases, working with therapeutic modalities like mRNA, AAV, antibodies, and oligonucleotides.<br /> He has successfully advanced multiple drug candidates through clinical trials and contributed to a marketed drug. Dr. Zhang also brings extensive experience in business development and alliance management. He holds dual PhDs in Immunology (NYU) and Chemistry (Peking Union Medical College), and completed postdoctoral training at Yale and Harvard, as well as a CEO program at Haas School of Business.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Jay Sarkar</h3> Researcher and Entrepreneur, Stanford University </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl04_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223860.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Jay Sarkar" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Sarkar is a researcher and entrepreneur with a background in applied physics and electrical engineering, which he utilizes to develop systems biology solutions for medicine. He built his first company off his foundational PhD work at Stanford University, where he pioneered the use the mRNA modality for transiently reprogramming cell epigenetics to specifically reset cellular age. The approach has grown as one of the hottest in the longevity community, with some of the largest startup investments in biotech history. He has now progressed to studying the broader problem of new modality integration and distribution in a variety of tissues.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Kevin Kim</h3> VP, Discovery, miRecule, Inc. </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl05_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/225754.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Kevin Kim" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Kevin is an experienced leader in RNA therapeutic discovery with a track record of successfully managing research organizations and executing multiple pipeline programs to overcome technical and developmental challenges to bring RNA therapies to the clinic for genetic disorders.<br /> Kevin received his doctoral degree at UCLA and worked with the world-renowned experts on neuromuscular diseases, Dr. Lee Rubin at Harvard University and Dr. Robert Baloh at Cedars- Sinai Hospital, to unravel the disease mechanisms and potential therapeutic pathways for devastating diseases such as ALS and CMT. Over a decade of experience in academia and in various industry settings (start-up, biotech and pharma) has culminated in multiple academic publications and patents as well as contribution to the development of the next generation stereopure ASO drugs for CNS diseases (Wave Life Sciences) and cardioprotective therapeutic (Stem Cell Theranostics) which are currently undergoing preclinical and clinical evaluations. As Senior Director of Discovery Biology at Sarepta Therapeutics, Kevin and his team enhanced the delivery of FDA-approved PMO platform and expanded the utility of the platform to discover novel RNA therapeutics for genetic diseases. Kevin is currently serving as VP of Discovery at miRecule, Inc.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Kinkini Roy</h3> Associate Director, Aviceda Therapeutics </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl06_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223861.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Kinkini Roy" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>After finishing PhD and postdoc study from University of Massachusetts Amherst, Kinkini Roy worked in industry for last 12 years in Boston Biotech as well as big corporation. Currently she is leading the program for the next-generation RNA therapeutics using a proprietary synthetic, high-affinity, multi-valent glycans that target extrahepatic cells and improve intracellular delivery and efficacy of siRNA, Anti- sense oligonucleotides, mRNA-based therapeutics, Crispr-Cas9 gene editing and lysosomal targeted protein degradation. Along with that she is leading the formulation development team and develop the formulation development strategy for pipeline development.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Martin Akerman</h3> CTO & Co-Founder, Envisagenics </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl07_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223857.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Martin Akerman" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Pushkar Saralkar</h3> Senior Scientist, Pfizer </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl08_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/225239.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Pushkar Saralkar" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Pushkar Saralkar is a Senior Scientist at Pfizer within the BioTherapeutics Pharmaceutical Research & Development organization in Andover, MA. Dr Saralkar is experienced in drug product development, with a particular interest in mRNA lipid nanoparticles. His research is broadly focused on developing delivery solutions to advance novel therapeutics into the clinic and is driven by developing breakthroughs that can change patient's lives.</p> <p>Dr Saralkar completed a Ph.D. (Pharmaceutical Science) in 2021 at West Virginia University with focus in nanoparticle-based drug delivery, CNS targeting and BBB pharmacokinetics. His research targeted mitochondrial protein mitoNEET to improve tissue survival following cerebral ischemia and reperfusion injury.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Richard Geary</h3> EVP, Chief Development Officer, Ionis Pharmaceuticals, Inc. </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl09_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223723.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Richard Geary" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Geary is the Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 50 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led six successful antisense medicine development programs through approvals in multiple jurisdictions.<br /> During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts. <br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Sandy Hinckley</h3> VP, Head of Discovery, QurAlis Corporation </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl10_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224684.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Sandy Hinckley" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Sandy Hinckley, Ph.D., is an accomplished drug-discovery scientist with a background as a human stem cell biologist and neuroscientist, focusing on disease modeling, therapeutic discovery, and translational research. Dr. Hinckley is currently vice president, head of discovery at QurAlis Corporation, a biotech company at the forefront of discovering and developing transformative precision medicines for neurodegenerative diseases, where she leads QurAlis' drug discovery efforts and biomarker strategies. She has worked at QurAlis since 2018, bringing forward two programs into clinical studies, including QRL-201, a splice-switching oligonucleotide for restoring STATHMIN-2 in sporadic ALS and other neurodegenerative diseases.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Sourav Choudhury</h3> Head AAV Technologies, Sanofi </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl11_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223858.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Sourav Choudhury" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.<br /> Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Steve Pascolo</h3> Founder and CEO, Miescher Pharma GmbH </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl12_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223868.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Steve Pascolo" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Trained as an immunologist at the Pasteur Institute (Paris, France), Prof. Steve Pascolo started working on mRNA vaccine in 1998 in Tuebingen, Germany. In 2000, he co-founded CureVac and was Chief Scientific Officer (CSO) of the company, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he left CureVac and continued the development of immunotherapies based on RNA at the University Hospital of Zurich. In 2008, he founded Miescher Pharma to support this work. In 2017, Prof. Pascolo implemented in the University of Zurich an academic mRNA platform. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Sudhir Agrawal</h3> Founder and President, ARNAY Sciences </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl13_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Sudhir Agrawal" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Sudhir Agrawal, D. Phil., FRSC, is the founder and President of ARNAY Sciences. He also serves as an Affiliate Professor in the Department of Medicine at UMass Chan Medical School. Over the last three decades, his research interest has been discovering and developing RNA therapeutics, including antisense and immunotherapy. He focuses on the chemical biology of nucleic acids for creating RNA therapeutics. He has published over 300 research papers and is listed as a co-inventor of more than 500 patents worldwide. He has edited four books on oligonucleotides and antisense technology, including a recent book on ‘Advances in Nucleic Acid Therapeutics’ by The Royal Society of Chemistry. He is currently serving as a member of the scientific advisory board of several biotechnology companies.</p> <p>He obtained his D.Phil. in Chemistry from Allahabad University in India and conducted postdoctoral research at MRC’s Laboratory of Molecular Biology, Cambridge, UK. His research in the antisense field started in Paul Zamecnik’s laboratory at the Worcester Foundation of Experimental Biology, now UMass Chan Medical School. He was a co-founder of Idera Pharmaceuticals and held various roles until 2017.</p> <p>In 2022, the Oligonucleotide Therapeutic Society awarded him the Lifetime Achievement Award.</p> <p> </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Yue Hui</h3> Scientist, Moderna </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl14_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223864.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Yue Hui" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>I earned my Ph.D. degree in Chemical Engineering from Caltech under Professor David A. Tirrell. In September 2022, I joined Moderna as a Scientist in Formulation Discovery. Here, I lead research initiatives focused on LNP process fundamentals and innovation, as well as novel LNP systems for both hepatic and extra-hepatic delivery of nucleic acids.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Zdravka Medarova</h3> Chief Scientific Officer, TransCode Therapeutics </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl15_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224685.png?width=200&height=190&bgcolor=white&scale=canvas" alt="Zdravka Medarova" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Zdravka Medarova, PhD has served as Scientific Co-Founder and a member of the advisory board of TransCode since January 2016. Dr.<br /> Medarova has been on the Faculty of Harvard Medical School and MGH since June 2007. She has served as an Associate Professor of Radiology at Harvard Medical School from April 2016 and as an Assistant in Neuroimaging at the Athinoula A. Martinos Center for Biomedical Imaging at MGH since June 2007. Dr. Medarova joined TransCode fulltime as the Chief Technology Officer on October 1, 2021. Dr. Medarova is a geneticist/cancer biologist by training and is internationally recognized for her work on non-coding RNA for cancer therapy. She is one of the first to describe the design and application of nanoparticles as carriers of siRNA to tumors. Since then, her research has focused on developing nanotechnology and imaging tools to better understand cancer initiation and progression and applying this knowledge to design clinically relevant therapeutic and diagnostic agents against cancer. Dr. Medarova obtained a B.A. in pre-medicine from the University of Southern Maine in September 1998 and a Ph.D. in Genetics from the University of New Hampshire in December 2002.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Zimeng Wang</h3> Senior Scientist, AstraZeneca </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl16_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/223859.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Zimeng Wang" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Zimeng is a senior scientist of Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca. His research in AZ includes formulation optimization to enhance the efficacy and safety of LNP vaccines, development of dry powder LNPs to improve RT stability, and development of LNPs for local/targeted delivery. Before joining AZ, he worked in Phosphorex Inc. on development of sustained release microspheres and targeted delivery nanoparticles. Zimeng got his PhD in University of Rhode Island focusing on development of dry powder aerosol nanocomposite microparticles for the treatment of pulmonary diseases.</p> </div> </div> <button title="Close (Esc)" type="button" class="mfp-close">×</button> </div> </div> <div id="ctl00_MainContent_divColumntext" class="columntext row" style="margin: 50px 0 50px 0;"> <div class="col-xs-12 col-sm-6"> <p>Whether you're new to the RNA space or at the forefront of RNA innovation, our 2-day conference is designed to meet your needs with a comprehensive agenda exploring the latest in RNA research and development.</p> <ul> <li>Engage, Collaborate, and Learn: Connect with peers to exchange ideas, collaborate on projects, and learn from both the successes and challenges in RNA discovery, development, delivery, and manufacturing.</li> <li>Stay Ahead of the Curve: Dive into sessions covering breakthroughs in mRNA technology, innovative delivery systems, and cutting-edge therapeutic applications. Gain insights from leading pharmaceutical companies such as Pfizer, Moderna, Sanofi, and AstraZeneca.</li> <li>Drive Innovation: Participate in discussions on the future of RNA therapeutics, including the role of AI and machine learning in drug discovery and development. Learn how to overcome current challenges and leverage new opportunities to stay competitive in this fast-evolving field.</li> </ul> <p><strong>Join us in October!</strong><br />  </p> </div> <div class="col-xs-12 col-sm-6"> <p><strong>Who Should Attend?</strong></p> <p>Join us at RNA Therapeutics USA and immerse yourself in a hub of innovation and expertise. Engage directly with top-tier professionals including Directors, Heads, and Principal Scientists specializing in RNA Drug Delivery/Development, Genetic Medicine, Analytical Development, CMC/Manufacturing, and Drug Discovery. This event offers a rare platform to delve into the latest scientific breakthroughs, explore cutting-edge technologies, and discuss strategic insights with pioneers shaping the future of RNA therapeutics. Elevate your knowledge, spark new ideas, and discover collaborative opportunities that can accelerate your research and development projects.</p> </div> </div> <div style="margin-top:20px;"> <script> $(window).ready(function () { $("#sponsors-slider").owlCarousel({ items: 2, center: true, autoPlay: 3000, //Set AutoPlay to 3 seconds slideSpeed: 600, loop: true }); }); </script> <div id="ctl00_MainContent_sponsorsPartnersScroller_divSponsorsScroller" class="container sponsors-home"> <div class="col-md-12"> <h2> sponsors</h2> <div id="sponsors-slider" class="slider hidden partner-slider"> <div class="sponsor-elem"><a href="#pop-sponsor-single" class="open-popup-link "><img class="sponsor-image" src="/_media/partners/4103.jpg?width=210&height=100" alt="ChemGenes" /></a><div class="hidden sponsor-name">ChemGenes</div><div class="hidden sponsor-link">http://www.chemgenes.com</div><div class="hidden sponsor-profile">ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.</div></div><div class="sponsor-elem"><a href="#pop-sponsor-single" class="open-popup-link "><img class="sponsor-image" src="/_media/partners/5639.png?width=210&height=100" alt="TriLink BioTechnologies" /></a><div class="hidden sponsor-name">TriLink BioTechnologies</div><div class="hidden sponsor-link">https://www.trilinkbiotech.com/</div><div class="hidden sponsor-profile"><p>TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.<p></div></div> </div>  </div> </div> </div> <div id="ctl00_MainContent_divLatestcontent" class="col-xs-12 col-sm-12 text-center latestcontent" style="padding-bottom:20px;"> <p><strong>Why not partner with us?</strong></p> <p><strong>By sponsoring, you’ll position your brand for success. Don't miss out on the opportunity to elevate your visibility, credibility, and business prospects—consider sponsorship today!</strong></p> <p><strong>Please contact Yasmin Alsadoon at <a href="mailto:Yasmin.Alsadoon@saemediagroup.com">Yasmin.Alsadoon@saemediagroup.com</a>or call +44 (0) 20 7827 6064</strong></p> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_programme"> <div class="programme2"> <script> $(document).ready(function () { $('.streamtabs a').click(function (event) { $(this).tab('show'); var target = $(this).attr('href'); $('html, body').animate({ scrollTop: $(target).offset().top }, 800); event.preventDefault(); return false; }); $('.daylist .nav-tabs > li > a, .daylist2 .nav-tabs > li > a').click(function (event) { var target = $(this).attr('href'); $(target).addClass('active').siblings().removeClass('active'); $('.daylist .nav-tabs .nav-link[href="' + target + '"], .daylist2 .nav-tabs .nav-link[href="' + target + '"]').parent().addClass('active').siblings().removeClass('active'); event.preventDefault(); }); }) function setActiveDay(dayNumber) { $('.daylist .nav-tabs li,.daylist2 .nav-tabs li').removeClass('active'); $('.daylist .nav-tabs li a[href*="#day_' + dayNumber + '"],.daylist2.nav - tabs li a[href *= "#day_' + dayNumber + '"]').parent().addClass('active'); } function updateURL(hash) { if (history.pushState) { history.pushState(null, null, hash); } else { location.hash = hash; } } </script> <h2>Conference agenda</h2> <div role="tabpanel" class="tabpanel"> <div class="daylist"> <ul class="nav nav-tabs" role="tablist" style="width:100%" > <li role="presentation" class="active"><a class="nav-link" href="#day_1" aria-controls="day_1" role="tab" data-toggle="tab" onclick="scrollToPosition(600);">Day one</a></li><li role="presentation" class=""><a class="nav-link" href="#day_2" aria-controls="day_2" role="tab" data-toggle="tab" onclick="scrollToPosition(600);">Day two</a></li> </ul> </div>  <div id="daycontent" class="tab-content"> <div role="tabpanel" class="tab-pane active" id="day_1"><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">8:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Registration & Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chair's Opening Remarks</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223857.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Martin Akerman" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Martin Akerman, </strong></span><span class="speaker-details">CTO & Co-Founder, <strong>Envisagenics</strong></span><div class="hidden speaker-profile"><p>Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Opening Address: Advancements in Antisense Therapy for Neurological Disorders</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223723.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Richard Geary" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Richard Geary, </strong></span><span class="speaker-details">EVP, Chief Development Officer, <strong>Ionis Pharmaceuticals, Inc.</strong></span><div class="hidden speaker-profile"><p>Dr. Geary is the Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 50 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led six successful antisense medicine development programs through approvals in multiple jurisdictions.<br /> During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts. <br />  </p></div><div class="topic-description"> <li>Utilising antisense technology to broaden therapeutic scope</li> <li>Case studies: nusinersen (Spinraza) in spinal muscular atrophy (SMA) for spinal muscular atrophy and tofersen (Qalsody) in ALS with SOD1</li> <li>mutations</li> <li>Opportunities in applying antisense technology as potential therapy for other neurodegenerative diseases and neurodevelopmental disorders</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Cyclic structured oligonucleotides for RNA therapeutics</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Sudhir Agrawal" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Sudhir Agrawal, </strong></span><span class="speaker-details">Founder and President, <strong>ARNAY Sciences</strong></span><div class="hidden speaker-profile"><p>Sudhir Agrawal, D. Phil., FRSC, is the founder and President of ARNAY Sciences. He also serves as an Affiliate Professor in the Department of Medicine at UMass Chan Medical School. Over the last three decades, his research interest has been discovering and developing RNA therapeutics, including antisense and immunotherapy. He focuses on the chemical biology of nucleic acids for creating RNA therapeutics. He has published over 300 research papers and is listed as a co-inventor of more than 500 patents worldwide. He has edited four books on oligonucleotides and antisense technology, including a recent book on ‘Advances in Nucleic Acid Therapeutics’ by The Royal Society of Chemistry. He is currently serving as a member of the scientific advisory board of several biotechnology companies.</p> <p>He obtained his D.Phil. in Chemistry from Allahabad University in India and conducted postdoctoral research at MRC’s Laboratory of Molecular Biology, Cambridge, UK. His research in the antisense field started in Paul Zamecnik’s laboratory at the Worcester Foundation of Experimental Biology, now UMass Chan Medical School. He was a co-founder of Idera Pharmaceuticals and held various roles until 2017.</p> <p>In 2022, the Oligonucleotide Therapeutic Society awarded him the Lifetime Achievement Award.</p> <p> </p></div><div class="topic-description"> <li>Sequence and chemistry are critical factors in providing drug-like properties to oligonucleotide</li> <li>In the early days, chemistry addressed the nuclease stability and affinity and allowed the design of gapmer antisense and modified RNA for splice modulation</li> <li>The discovery of Pattern Recognition receptors (PRRs) provided insights into immune activation by oligonucleotides, and SAR studies provided details on modifications to mitigate immune activation.</li> <li>New generations of antisense are designed using lessons learned during studies with PRRs, shapes, and useful chemical modifications</li> <li>Transient cyclic structures of oligonucleotide provide efficient delivery of therapeutics to cellular compartments, resulting in increased potency and specificity<br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">10:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Morning Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Recent Advances in the Development of Splice-Switching Oligonucleotides for CNS Diseases</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224684.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Sandy Hinckley" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Sandy Hinckley, </strong></span><span class="speaker-details">VP, Head of Discovery, <strong>QurAlis Corporation</strong></span><div class="hidden speaker-profile"><p>Sandy Hinckley, Ph.D., is an accomplished drug-discovery scientist with a background as a human stem cell biologist and neuroscientist, focusing on disease modeling, therapeutic discovery, and translational research. Dr. Hinckley is currently vice president, head of discovery at QurAlis Corporation, a biotech company at the forefront of discovering and developing transformative precision medicines for neurodegenerative diseases, where she leads QurAlis' drug discovery efforts and biomarker strategies. She has worked at QurAlis since 2018, bringing forward two programs into clinical studies, including QRL-201, a splice-switching oligonucleotide for restoring STATHMIN-2 in sporadic ALS and other neurodegenerative diseases.</p></div><div class="topic-description"> <li>Pre-mRNA mis-splicing is a recurring theme in neurodegenerative diseases</li> <li>Splice switching ASOs provide a powerful modality to correct these errors</li> <li>QurAlis’ FlexASO™ platform enables the construction of splice switching ASOs with enhanced potency, safety, and biodistribution properties</li> <li>This platform generally and in the context of our discovery programs will be discussed<br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">RNA Therapeutics development with AI/ML</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223857.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Martin Akerman" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Martin Akerman, </strong></span><span class="speaker-details">CTO & Co-Founder, <strong>Envisagenics</strong></span><div class="hidden speaker-profile"><p>Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.</p></div><div class="topic-description"> <li>Introducing SpliceCore, an AI-driven platform developed by Envisagenics, tailored to uncover novel therapeutic targets for neurodegenerative diseases like ALS, leveraging the intricate process of alternative splicing which is crucial in neuronal function and disease</li> <li>Decoding ALS with SpliceCore: We will explore the scientific premise of alternative splicing, and the use of AI/ML to develop splicing modulatory drugs to treat sporadic ALS</li> <li>SpliceCore’s predictive power has been validated experimentally, demonstrating its efficacy in identifying novel antisense drug targets for neurodegeneration</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">12:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Networking Lunch</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">13:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Key Considerations for Targeted Delivery of RNA</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223861.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Kinkini Roy" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Kinkini Roy, </strong></span><span class="speaker-details">Associate Director, <strong>Aviceda Therapeutics</strong></span><div class="hidden speaker-profile"><p>After finishing PhD and postdoc study from University of Massachusetts Amherst, Kinkini Roy worked in industry for last 12 years in Boston Biotech as well as big corporation. Currently she is leading the program for the next-generation RNA therapeutics using a proprietary synthetic, high-affinity, multi-valent glycans that target extrahepatic cells and improve intracellular delivery and efficacy of siRNA, Anti- sense oligonucleotides, mRNA-based therapeutics, Crispr-Cas9 gene editing and lysosomal targeted protein degradation. Along with that she is leading the formulation development team and develop the formulation development strategy for pipeline development.</p></div><div class="topic-description"> <li>Importance of targeted delivery for maximizing therapeutic efficacy and minimizing off-target effects</li> <li>Strategies and technologies to achieve controlled and efficient targeted RNA delivery</li> <li>Active vs. Passive Targeting: Comparing targeting methods, their mechanisms, advantages, and applications in RNA therapeutics</li> <li>Major obstacles in targeted RNA delivery and potential ways to address these challenges</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Development of 3-component LNP with fast shedding off PEG copolymer coating</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223859.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Zimeng Wang" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Zimeng Wang, </strong></span><span class="speaker-details">Senior Scientist, <strong>AstraZeneca</strong></span><div class="hidden speaker-profile"><p>Zimeng is a senior scientist of Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca. His research in AZ includes formulation optimization to enhance the efficacy and safety of LNP vaccines, development of dry powder LNPs to improve RT stability, and development of LNPs for local/targeted delivery. Before joining AZ, he worked in Phosphorex Inc. on development of sustained release microspheres and targeted delivery nanoparticles. Zimeng got his PhD in University of Rhode Island focusing on development of dry powder aerosol nanocomposite microparticles for the treatment of pulmonary diseases.</p></div><div class="topic-description"> <li>PEG-lipid in LNP brings “PEG dilemma”: (1) PEG-lipid is essential to achieve desired LNP size during fabrication and maintain the colloidal stability during storage; (2) PEG-lipid could reduce the cell uptake and induce PEG-specific antibodies increasing the clearance rate of PEGylated LNP</li> <li>PEG copolymer coating could be a potential solution to “PEG dilemma”, which maintains particle size during storage but sheds off quickly after administration to improve the in vivo efficacy</li> <li>In this study, we optimized both the fabrication process and LNP composition to ensure desired physicochemical properties and efficacy of poloxamer 407 (P407) coated LNP</li> <li>In vivo study using luciferase mRNA showed initial P407 coated formulation led to increased spleen and lung mRNA distribution comparing to the LNP with PEG-lipid. However, lower luciferase protein level in organs indicated that further optimization is required to improve the LNP efficacy</li> <li>The optimized LNP with increased phospholipid ratio significantly improved the in vitro efficacy of P407 coated LNP</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Afternoon Break</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Optimizing RNA Therapeutics: ML-Powered Development, Novel Delivery Platforms, and Pipeline Expansion</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Jason Zhang" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Jason Zhang, </strong></span><span class="speaker-details">Co-Founder and CEO, <strong>Zipcode Bio</strong></span><div class="hidden speaker-profile"><p>Dr. Jason Zhang is the Co-Founder and CEO of Zipcode Bio, a leading biotechnology company developing next-generation nucleic acid-based medicines. Before founding Zipcode Bio, he was CSO at two biotech firms, overseeing preclinical R&D and pipeline strategy. Dr. Zhang has broad expertise in oncology, immunology, neurology, and infectious diseases, working with therapeutic modalities like mRNA, AAV, antibodies, and oligonucleotides.<br /> He has successfully advanced multiple drug candidates through clinical trials and contributed to a marketed drug. Dr. Zhang also brings extensive experience in business development and alliance management. He holds dual PhDs in Immunology (NYU) and Chemistry (Peking Union Medical College), and completed postdoctoral training at Yale and Harvard, as well as a CEO program at Haas School of Business.<br />  </p></div><div class="topic-description"> <li>Utilizing advanced machine learning models to accelerate design and optimization, enabling faster and more precise development of RNA-based therapies.</li> <li>Pushing the front of mRNA medicines via traditional LNPs and novel SHARP platform to redefine the landscape of mRNA delivery for enhanced therapeutic efficacy.</li> <li>Unveiling Zipcode Bio’s immunology pipeline including innovative mRNA vaccines and therapeutics<br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Novel Constructs for Network Mediated Large Molecule Drug Delivery</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223860.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Jay Sarkar" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Jay Sarkar, </strong></span><span class="speaker-details">Researcher and Entrepreneur, <strong>Stanford University</strong></span><div class="hidden speaker-profile"><p>Dr. Sarkar is a researcher and entrepreneur with a background in applied physics and electrical engineering, which he utilizes to develop systems biology solutions for medicine. He built his first company off his foundational PhD work at Stanford University, where he pioneered the use the mRNA modality for transiently reprogramming cell epigenetics to specifically reset cellular age. The approach has grown as one of the hottest in the longevity community, with some of the largest startup investments in biotech history. He has now progressed to studying the broader problem of new modality integration and distribution in a variety of tissues.</p></div><div class="topic-description"> <li>Drug Routers and the Network Paradigm for Drug Delivery</li> <li>Analysis of Router Induced Networks</li> <li>Distributable Cargo and Cell Type Diversity</li> <li>In Vivo Delivery and Continuing Studies</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">16:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chair’s Closing Remarks and Close of Day One</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223857.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Martin Akerman" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Martin Akerman, </strong></span><span class="speaker-details">CTO & Co-Founder, <strong>Envisagenics</strong></span><div class="hidden speaker-profile"><p>Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">16:25</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">End of Day One Networking Drinks Reception</h3></div></div></div></div></div><div role="tabpanel" class="tab-pane" id="day_2"><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">8:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Registration & Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chair's Opening Remarks</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223858.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Sourav Choudhury" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Sourav Choudhury, </strong></span><span class="speaker-details">Head AAV Technologies, <strong>Sanofi</strong></span><div class="hidden speaker-profile"><p>Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.<br /> Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.<br />  </p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Advancing Gene Delivery Vehicles with AI/ML</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223858.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Sourav Choudhury" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Sourav Choudhury, </strong></span><span class="speaker-details">Head AAV Technologies, <strong>Sanofi</strong></span><div class="hidden speaker-profile"><p>Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.<br /> Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.<br />  </p></div><div class="topic-description"> <li>Insight into use of viral delivery platforms for improved delivery</li> <li>Opportunities to advance capsid development and further understand capsid functioning through use of AI</li> <li>Examples of machine learning guided capsid development</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">mRNA process science and engineering: first steps towards a novel modality</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223864.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Yue Hui" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Yue Hui, </strong></span><span class="speaker-details">Scientist, <strong>Moderna</strong></span><div class="hidden speaker-profile"><p>I earned my Ph.D. degree in Chemical Engineering from Caltech under Professor David A. Tirrell. In September 2022, I joined Moderna as a Scientist in Formulation Discovery. Here, I lead research initiatives focused on LNP process fundamentals and innovation, as well as novel LNP systems for both hepatic and extra-hepatic delivery of nucleic acids.</p></div><div class="topic-description"> <li>mRNA as a new modality for vaccines and therapeutics</li> <li>Fundamentals on LNP assembly: understanding the impact of fluid dynamics</li> <li>A case study on CMV vaccine</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">10:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Morning Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Formulation considerations for mRNA-lipid nanoparticles: vaccines and beyond</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/225239.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Pushkar Saralkar" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Pushkar Saralkar, </strong></span><span class="speaker-details">Senior Scientist, <strong>Pfizer</strong></span><div class="hidden speaker-profile"><p>Pushkar Saralkar is a Senior Scientist at Pfizer within the BioTherapeutics Pharmaceutical Research & Development organization in Andover, MA. Dr Saralkar is experienced in drug product development, with a particular interest in mRNA lipid nanoparticles. His research is broadly focused on developing delivery solutions to advance novel therapeutics into the clinic and is driven by developing breakthroughs that can change patient's lives.</p> <p>Dr Saralkar completed a Ph.D. (Pharmaceutical Science) in 2021 at West Virginia University with focus in nanoparticle-based drug delivery, CNS targeting and BBB pharmacokinetics. His research targeted mitochondrial protein mitoNEET to improve tissue survival following cerebral ischemia and reperfusion injury.<br />  </p></div><div class="topic-description"> <li>Formulation aspects of lipid nanoparticles that enabled the success of mRNA as a vaccine</li> <li>Challenges in formulation and process parameters during product development of mRNA-lipid nanoparticles</li> <li>Considerations when designing mRNA-lipid nanoparticle drug products as a therapeutic vs. vaccine</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Practical Application of Platform Analytical Procedures in Late-Stage Development of mRNA</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223856.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Hetal Patel" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Hetal Patel, </strong></span><span class="speaker-details">Senior Principle Scientist/Group Leader, <strong>Pfizer</strong></span><div class="hidden speaker-profile"><p>I am a group leader/Senior Principal Scientist at Pfizer Analytical Research and Development managing early and late-stage method validation and transfers. <br /> I have a masters in organic chemistry, Ph.D. in protein chemistry/biochemistry from Rutgers University and Postdoctoral from Albert Einstein, NY. I pursued MBA in management from Babson (finance, leadership excellence, people management) during my tenure at Pfizer. <br /> I have hands on experience working with mAbs, mRNA, small molecules, including small molecule synthesis, protein expression, variety of chromatographic/spectroscopic techniques, biochemical and biophysical characterization technologies, GMP inspections/audits, regulatory submissions/query responses. Lately, I have been actively leading implementation of ICH Q2 (R2) and ICH Q14 approaches around using prior knowledge and abbreviated validations in late-stage mRNA and mAb product development.<br />  </p></div><div class="topic-description"> <li>Practical applications of platform analytical procedures leveraging guidance from ICH Q2 (R2) and ICH Q14 and the challenges associated with this paradigm shift</li> <li>Using prior knowledge, experience and historical data to expand the application of platform analytical procedures to reduce redundant work and enable a strong scientific justification for approach to an abbreviated validation in late-stage</li> <li>How prior knowledge including method validation and transfer may be used to enable rapid commercial readiness with streamlined approach</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">12:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Networking Lunch</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">13:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">The role of adjuvants in vaccine development</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223867.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Derek O Hagan" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Derek O Hagan, </strong></span><span class="speaker-details">Senior Advisor R&D, <strong>GSK</strong></span><div class="hidden speaker-profile"><p>I am currently a Senior Advisor in GSK Vaccines R&D. Prior to my current role I was the Global Head of Discovery Support and New Technology in GSK. Previously, I was VP, Global Head of Vaccine Chemistry and Formulation for Novartis Vaccines. I have extensive experience on Vaccine Adjuvants, including R&D on several included in licensed products, and I was a member of the Team that initiated work on RNA vaccines in Novartis in 2009. I am a Fellow of the American Association of Pharmaceutical Scientists. I was previously awarded the Conference Science medal of the Royal Pharmaceutical Society of Great Britain, and the Young Investigator Research Achievement Award of the Controlled Release Society. I was named as the ‘most inventive scientist’ in Chiron Corp, Emeryville.</p> <ul> <li>175 peer reviewed publications (h-index 105, Google Scholar)</li> <li>Named inventor on >70+ patents<br />  </li> </ul></div><div class="topic-description"> <li>Reviewing the mechanisms and science behind adjuvants, and how they enhance immune responses</li> <li>Exploring the potential of adjuvants to improve the performance of RNA vaccines</li> <li>Future outlook: what will the next generation of adjuvants look like?</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">mRNA Vaccines: The past, present and future directions for advancing</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223868.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Steve Pascolo" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Steve Pascolo, </strong></span><span class="speaker-details">Founder and CEO, <strong>Miescher Pharma GmbH</strong></span><div class="hidden speaker-profile"><p>Trained as an immunologist at the Pasteur Institute (Paris, France), Prof. Steve Pascolo started working on mRNA vaccine in 1998 in Tuebingen, Germany. In 2000, he co-founded CureVac and was Chief Scientific Officer (CSO) of the company, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he left CureVac and continued the development of immunotherapies based on RNA at the University Hospital of Zurich. In 2008, he founded Miescher Pharma to support this work. In 2017, Prof. Pascolo implemented in the University of Zurich an academic mRNA platform. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.</p></div><div class="topic-description"> <li>History of mRNA vaccines and how they have developed since COVID-19</li> <li>Insight into the mode of action of synthetic vs natural mRNA vaccines</li> <li>Effective formulation and production strategies to implement for mRNA vaccine development</li> <li>Evaluating the current vaccines and therapies based on synthetic mRNA currently in the market and the key takeaways</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Afternoon Break</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Fireside Chat: The Future of RNA Therapeutics: Innovations, Technologies, and Modalities</h3></div></div></div><div class="keynote-speaker clearfix"><div class="col-xs-2" style="float: left; padding-left:5px"></div><div class="col-xs-10" style="overflow:auto;"><div class="topic-description"> <li>Exploring the potential next wave of RNA-based therapeutics oised to hit the market. What are the technologies and research areas that the industry should prioritize and develop?</li> <li>Platforms for developing delivery vectors: latest platforms and strategies for creating effective and reliable delivery vectors</li> <li>Future opportunities for furthering innovation and strategic collaborations</li> </div></div></p></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223858.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Sourav Choudhury" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Sourav Choudhury, </strong></span><span class="speaker-details">Head AAV Technologies, <strong>Sanofi</strong></span><div class="hidden speaker-profile"><p>Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.<br /> Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.<br />  </p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223868.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Steve Pascolo" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Steve Pascolo, </strong></span><span class="speaker-details">Founder and CEO, <strong>Miescher Pharma GmbH</strong></span><div class="hidden speaker-profile"><p>Trained as an immunologist at the Pasteur Institute (Paris, France), Prof. Steve Pascolo started working on mRNA vaccine in 1998 in Tuebingen, Germany. In 2000, he co-founded CureVac and was Chief Scientific Officer (CSO) of the company, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he left CureVac and continued the development of immunotherapies based on RNA at the University Hospital of Zurich. In 2008, he founded Miescher Pharma to support this work. In 2017, Prof. Pascolo implemented in the University of Zurich an academic mRNA platform. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/225754.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Kevin Kim" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Kevin Kim, </strong></span><span class="speaker-details">VP, Discovery, <strong>miRecule, Inc.</strong></span><div class="hidden speaker-profile"><p>Kevin is an experienced leader in RNA therapeutic discovery with a track record of successfully managing research organizations and executing multiple pipeline programs to overcome technical and developmental challenges to bring RNA therapies to the clinic for genetic disorders.<br /> Kevin received his doctoral degree at UCLA and worked with the world-renowned experts on neuromuscular diseases, Dr. Lee Rubin at Harvard University and Dr. Robert Baloh at Cedars- Sinai Hospital, to unravel the disease mechanisms and potential therapeutic pathways for devastating diseases such as ALS and CMT. Over a decade of experience in academia and in various industry settings (start-up, biotech and pharma) has culminated in multiple academic publications and patents as well as contribution to the development of the next generation stereopure ASO drugs for CNS diseases (Wave Life Sciences) and cardioprotective therapeutic (Stem Cell Theranostics) which are currently undergoing preclinical and clinical evaluations. As Senior Director of Discovery Biology at Sarepta Therapeutics, Kevin and his team enhanced the delivery of FDA-approved PMO platform and expanded the utility of the platform to discover novel RNA therapeutics for genetic diseases. Kevin is currently serving as VP of Discovery at miRecule, Inc.<br />  </p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chair’s Closing Remarks and Close of Day Two</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/223858.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Sourav Choudhury" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Sourav Choudhury, </strong></span><span class="speaker-details">Head AAV Technologies, <strong>Sanofi</strong></span><div class="hidden speaker-profile"><p>Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.<br /> Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.<br />  </p></div></div></div></div></div> </div>  <div class="daylist2"> <ul class="nav nav-tabs" role="tablist" > <li role="presentation" class="active"><a class="nav-link" href="#day_1" aria-controls="day_1" role="tab" data-toggle="tab" onclick="scrollToPosition(600);">Day one</a></li><li role="presentation" class=""><a class="nav-link" href="#day_2" aria-controls="day_2" role="tab" data-toggle="tab" onclick="scrollToPosition(600);">Day two</a></li> </ul> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_speakers"> <div id="speaker-grid"> <div id="pop-speakers-all" class="container-fluid" style="margin-bottom: 20px;"> <br> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl01_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223867.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Derek O Hagan" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Derek O Hagan</a></div> <div style="margin-top:5px"">Senior Advisor R&D</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">GSK</div> <div class="hidden speaker-details">Senior Advisor R&D, GSK</div> <div class="hidden speaker-profile"><p>I am currently a Senior Advisor in GSK Vaccines R&D. Prior to my current role I was the Global Head of Discovery Support and New Technology in GSK. Previously, I was VP, Global Head of Vaccine Chemistry and Formulation for Novartis Vaccines. I have extensive experience on Vaccine Adjuvants, including R&D on several included in licensed products, and I was a member of the Team that initiated work on RNA vaccines in Novartis in 2009. I am a Fellow of the American Association of Pharmaceutical Scientists. I was previously awarded the Conference Science medal of the Royal Pharmaceutical Society of Great Britain, and the Young Investigator Research Achievement Award of the Controlled Release Society. I was named as the ‘most inventive scientist’ in Chiron Corp, Emeryville.</p> <ul> <li>175 peer reviewed publications (h-index 105, Google Scholar)</li> <li>Named inventor on >70+ patents<br />  </li> </ul></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl02_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223856.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Hetal Patel" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Hetal Patel</a></div> <div style="margin-top:5px"">Senior Principle Scientist/Group Leader</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Pfizer</div> <div class="hidden speaker-details">Senior Principle Scientist/Group Leader, Pfizer</div> <div class="hidden speaker-profile"><p>I am a group leader/Senior Principal Scientist at Pfizer Analytical Research and Development managing early and late-stage method validation and transfers. <br /> I have a masters in organic chemistry, Ph.D. in protein chemistry/biochemistry from Rutgers University and Postdoctoral from Albert Einstein, NY. I pursued MBA in management from Babson (finance, leadership excellence, people management) during my tenure at Pfizer. <br /> I have hands on experience working with mAbs, mRNA, small molecules, including small molecule synthesis, protein expression, variety of chromatographic/spectroscopic techniques, biochemical and biophysical characterization technologies, GMP inspections/audits, regulatory submissions/query responses. Lately, I have been actively leading implementation of ICH Q2 (R2) and ICH Q14 approaches around using prior knowledge and abbreviated validations in late-stage mRNA and mAb product development.<br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl03_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Jason Zhang" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Jason Zhang</a></div> <div style="margin-top:5px"">Co-Founder and CEO</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Zipcode Bio</div> <div class="hidden speaker-details">Co-Founder and CEO, Zipcode Bio</div> <div class="hidden speaker-profile"><p>Dr. Jason Zhang is the Co-Founder and CEO of Zipcode Bio, a leading biotechnology company developing next-generation nucleic acid-based medicines. Before founding Zipcode Bio, he was CSO at two biotech firms, overseeing preclinical R&D and pipeline strategy. Dr. Zhang has broad expertise in oncology, immunology, neurology, and infectious diseases, working with therapeutic modalities like mRNA, AAV, antibodies, and oligonucleotides.<br /> He has successfully advanced multiple drug candidates through clinical trials and contributed to a marketed drug. Dr. Zhang also brings extensive experience in business development and alliance management. He holds dual PhDs in Immunology (NYU) and Chemistry (Peking Union Medical College), and completed postdoctoral training at Yale and Harvard, as well as a CEO program at Haas School of Business.<br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl04_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223860.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Jay Sarkar" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Jay Sarkar</a></div> <div style="margin-top:5px"">Researcher and Entrepreneur</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Stanford University</div> <div class="hidden speaker-details">Researcher and Entrepreneur, Stanford University</div> <div class="hidden speaker-profile"><p>Dr. Sarkar is a researcher and entrepreneur with a background in applied physics and electrical engineering, which he utilizes to develop systems biology solutions for medicine. He built his first company off his foundational PhD work at Stanford University, where he pioneered the use the mRNA modality for transiently reprogramming cell epigenetics to specifically reset cellular age. The approach has grown as one of the hottest in the longevity community, with some of the largest startup investments in biotech history. He has now progressed to studying the broader problem of new modality integration and distribution in a variety of tissues.</p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl05_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/225754.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Kevin Kim" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Kevin Kim</a></div> <div style="margin-top:5px"">VP, Discovery</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">miRecule, Inc.</div> <div class="hidden speaker-details">VP, Discovery, miRecule, Inc.</div> <div class="hidden speaker-profile"><p>Kevin is an experienced leader in RNA therapeutic discovery with a track record of successfully managing research organizations and executing multiple pipeline programs to overcome technical and developmental challenges to bring RNA therapies to the clinic for genetic disorders.<br /> Kevin received his doctoral degree at UCLA and worked with the world-renowned experts on neuromuscular diseases, Dr. Lee Rubin at Harvard University and Dr. Robert Baloh at Cedars- Sinai Hospital, to unravel the disease mechanisms and potential therapeutic pathways for devastating diseases such as ALS and CMT. Over a decade of experience in academia and in various industry settings (start-up, biotech and pharma) has culminated in multiple academic publications and patents as well as contribution to the development of the next generation stereopure ASO drugs for CNS diseases (Wave Life Sciences) and cardioprotective therapeutic (Stem Cell Theranostics) which are currently undergoing preclinical and clinical evaluations. As Senior Director of Discovery Biology at Sarepta Therapeutics, Kevin and his team enhanced the delivery of FDA-approved PMO platform and expanded the utility of the platform to discover novel RNA therapeutics for genetic diseases. Kevin is currently serving as VP of Discovery at miRecule, Inc.<br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl06_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223861.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Kinkini Roy" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Kinkini Roy</a></div> <div style="margin-top:5px"">Associate Director</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Aviceda Therapeutics</div> <div class="hidden speaker-details">Associate Director, Aviceda Therapeutics</div> <div class="hidden speaker-profile"><p>After finishing PhD and postdoc study from University of Massachusetts Amherst, Kinkini Roy worked in industry for last 12 years in Boston Biotech as well as big corporation. Currently she is leading the program for the next-generation RNA therapeutics using a proprietary synthetic, high-affinity, multi-valent glycans that target extrahepatic cells and improve intracellular delivery and efficacy of siRNA, Anti- sense oligonucleotides, mRNA-based therapeutics, Crispr-Cas9 gene editing and lysosomal targeted protein degradation. Along with that she is leading the formulation development team and develop the formulation development strategy for pipeline development.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl07_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223857.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Martin Akerman" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Martin Akerman</a></div> <div style="margin-top:5px"">CTO & Co-Founder</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Envisagenics</div> <div class="hidden speaker-details">CTO & Co-Founder, Envisagenics</div> <div class="hidden speaker-profile"><p>Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl08_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/225239.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Pushkar Saralkar" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Pushkar Saralkar</a></div> <div style="margin-top:5px"">Senior Scientist</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Pfizer</div> <div class="hidden speaker-details">Senior Scientist, Pfizer</div> <div class="hidden speaker-profile"><p>Pushkar Saralkar is a Senior Scientist at Pfizer within the BioTherapeutics Pharmaceutical Research & Development organization in Andover, MA. Dr Saralkar is experienced in drug product development, with a particular interest in mRNA lipid nanoparticles. His research is broadly focused on developing delivery solutions to advance novel therapeutics into the clinic and is driven by developing breakthroughs that can change patient's lives.</p> <p>Dr Saralkar completed a Ph.D. (Pharmaceutical Science) in 2021 at West Virginia University with focus in nanoparticle-based drug delivery, CNS targeting and BBB pharmacokinetics. His research targeted mitochondrial protein mitoNEET to improve tissue survival following cerebral ischemia and reperfusion injury.<br />  </p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl09_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223723.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Richard Geary" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Richard Geary</a></div> <div style="margin-top:5px"">EVP, Chief Development Officer</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Ionis Pharmaceuticals, Inc.</div> <div class="hidden speaker-details">EVP, Chief Development Officer, Ionis Pharmaceuticals, Inc.</div> <div class="hidden speaker-profile"><p>Dr. Geary is the Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 50 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led six successful antisense medicine development programs through approvals in multiple jurisdictions.<br /> During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts. <br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl10_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224684.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Sandy Hinckley" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Sandy Hinckley</a></div> <div style="margin-top:5px"">VP, Head of Discovery</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">QurAlis Corporation</div> <div class="hidden speaker-details">VP, Head of Discovery, QurAlis Corporation</div> <div class="hidden speaker-profile"><p>Sandy Hinckley, Ph.D., is an accomplished drug-discovery scientist with a background as a human stem cell biologist and neuroscientist, focusing on disease modeling, therapeutic discovery, and translational research. Dr. Hinckley is currently vice president, head of discovery at QurAlis Corporation, a biotech company at the forefront of discovering and developing transformative precision medicines for neurodegenerative diseases, where she leads QurAlis' drug discovery efforts and biomarker strategies. She has worked at QurAlis since 2018, bringing forward two programs into clinical studies, including QRL-201, a splice-switching oligonucleotide for restoring STATHMIN-2 in sporadic ALS and other neurodegenerative diseases.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl11_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223858.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Sourav Choudhury" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Sourav Choudhury</a></div> <div style="margin-top:5px"">Head AAV Technologies</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Sanofi</div> <div class="hidden speaker-details">Head AAV Technologies, Sanofi</div> <div class="hidden speaker-profile"><p>Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.<br /> Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.<br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl12_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223868.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Steve Pascolo" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Steve Pascolo</a></div> <div style="margin-top:5px"">Founder and CEO</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Miescher Pharma GmbH</div> <div class="hidden speaker-details">Founder and CEO, Miescher Pharma GmbH</div> <div class="hidden speaker-profile"><p>Trained as an immunologist at the Pasteur Institute (Paris, France), Prof. Steve Pascolo started working on mRNA vaccine in 1998 in Tuebingen, Germany. In 2000, he co-founded CureVac and was Chief Scientific Officer (CSO) of the company, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he left CureVac and continued the development of immunotherapies based on RNA at the University Hospital of Zurich. In 2008, he founded Miescher Pharma to support this work. In 2017, Prof. Pascolo implemented in the University of Zurich an academic mRNA platform. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.</p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl13_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Sudhir Agrawal" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Sudhir Agrawal</a></div> <div style="margin-top:5px"">Founder and President</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">ARNAY Sciences</div> <div class="hidden speaker-details">Founder and President, ARNAY Sciences</div> <div class="hidden speaker-profile"><p>Sudhir Agrawal, D. Phil., FRSC, is the founder and President of ARNAY Sciences. He also serves as an Affiliate Professor in the Department of Medicine at UMass Chan Medical School. Over the last three decades, his research interest has been discovering and developing RNA therapeutics, including antisense and immunotherapy. He focuses on the chemical biology of nucleic acids for creating RNA therapeutics. He has published over 300 research papers and is listed as a co-inventor of more than 500 patents worldwide. He has edited four books on oligonucleotides and antisense technology, including a recent book on ‘Advances in Nucleic Acid Therapeutics’ by The Royal Society of Chemistry. He is currently serving as a member of the scientific advisory board of several biotechnology companies.</p> <p>He obtained his D.Phil. in Chemistry from Allahabad University in India and conducted postdoctoral research at MRC’s Laboratory of Molecular Biology, Cambridge, UK. His research in the antisense field started in Paul Zamecnik’s laboratory at the Worcester Foundation of Experimental Biology, now UMass Chan Medical School. He was a co-founder of Idera Pharmaceuticals and held various roles until 2017.</p> <p>In 2022, the Oligonucleotide Therapeutic Society awarded him the Lifetime Achievement Award.</p> <p> </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl14_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223864.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Yue Hui" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Yue Hui</a></div> <div style="margin-top:5px"">Scientist</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Moderna</div> <div class="hidden speaker-details">Scientist, Moderna</div> <div class="hidden speaker-profile"><p>I earned my Ph.D. degree in Chemical Engineering from Caltech under Professor David A. Tirrell. In September 2022, I joined Moderna as a Scientist in Formulation Discovery. Here, I lead research initiatives focused on LNP process fundamentals and innovation, as well as novel LNP systems for both hepatic and extra-hepatic delivery of nucleic acids.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl15_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224685.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Zdravka Medarova" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Zdravka Medarova</a></div> <div style="margin-top:5px"">Chief Scientific Officer</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">TransCode Therapeutics</div> <div class="hidden speaker-details">Chief Scientific Officer, TransCode Therapeutics</div> <div class="hidden speaker-profile"><p>Zdravka Medarova, PhD has served as Scientific Co-Founder and a member of the advisory board of TransCode since January 2016. Dr.<br /> Medarova has been on the Faculty of Harvard Medical School and MGH since June 2007. She has served as an Associate Professor of Radiology at Harvard Medical School from April 2016 and as an Assistant in Neuroimaging at the Athinoula A. Martinos Center for Biomedical Imaging at MGH since June 2007. Dr. Medarova joined TransCode fulltime as the Chief Technology Officer on October 1, 2021. Dr. Medarova is a geneticist/cancer biologist by training and is internationally recognized for her work on non-coding RNA for cancer therapy. She is one of the first to describe the design and application of nanoparticles as carriers of siRNA to tumors. Since then, her research has focused on developing nanotechnology and imaging tools to better understand cancer initiation and progression and applying this knowledge to design clinically relevant therapeutic and diagnostic agents against cancer. Dr. Medarova obtained a B.A. in pre-medicine from the University of Southern Maine in September 1998 and a Ph.D. in Genetics from the University of New Hampshire in December 2002.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl16_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/223859.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Zimeng Wang" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Zimeng Wang</a></div> <div style="margin-top:5px"">Senior Scientist</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">AstraZeneca</div> <div class="hidden speaker-details">Senior Scientist, AstraZeneca</div> <div class="hidden speaker-profile"><p>Zimeng is a senior scientist of Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca. His research in AZ includes formulation optimization to enhance the efficacy and safety of LNP vaccines, development of dry powder LNPs to improve RT stability, and development of LNPs for local/targeted delivery. Before joining AZ, he worked in Phosphorex Inc. on development of sustained release microspheres and targeted delivery nanoparticles. Zimeng got his PhD in University of Rhode Island focusing on development of dry powder aerosol nanocomposite microparticles for the treatment of pulmonary diseases.</p></div> </div> </div> </div> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_sponsors"> <div class="sponsor_new sponsor-elem"> </div> <div class="other_sponser_sec"> <div class="container-fluid"> <div class="col-md-12" style=""> <h3>Exhibitors</h3> <ul style="float: none; text-align: center;"> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl06_rptSponsors_ctl01_imgSponsor" class="sponsor-image" src="/_media/partners/4103.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl01_lblName" class="hidden sponsor-name">ChemGenes</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl01_lblType" class="hidden sponsor-type">Exhibitors</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl01_lblLink" class="hidden sponsor-link">http://www.chemgenes.com</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl01_lblProfile" class="hidden sponsor-profile">ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl06_rptSponsors_ctl02_imgSponsor" class="sponsor-image" src="/_media/partners/5639.png?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl02_lblName" class="hidden sponsor-name">TriLink BioTechnologies</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl02_lblType" class="hidden sponsor-type">Exhibitors</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl02_lblLink" class="hidden sponsor-link">https://www.trilinkbiotech.com/</span> <span id="ctl00_MainContent_ctl06_rptSponsors_ctl02_lblProfile" class="hidden sponsor-profile"><p>TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.<p></span> </div> </li> </ul> </div> </div> <div class="clearfix"></div> <div class="buttons buttons_ed" style="margin-bottom: 40px;"> <a id="ctl00_MainContent_ctl06_rptSponsors_ctl03_lnkPopup" class="button-white open-popup-link" href="#pop-exhibitors">view all Exhibitors</a> <a href="#pop-sponsor" class="button-white open-popup-link">Sponsor the conference</a> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_partners"> <div class="sponsor_new sponsor-elem"> </div> <div class="sponsor_new sponsor-elem"> </div> <div class="other_sponser_sec"> <div class="container-fluid"> <div class="col-md-12" style=""> <h3>Supporters</h3> <ul style="float: none; text-align: center;"> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl10_rptSponsors_ctl01_imgSponsor" class="sponsor-image" src="/_media/partners/2411.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl10_rptSponsors_ctl01_lblName" class="hidden sponsor-name">pharmaphorum</span> <span id="ctl00_MainContent_ctl10_rptSponsors_ctl01_lblType" class="hidden sponsor-type">Supporters</span> <span id="ctl00_MainContent_ctl10_rptSponsors_ctl01_lblLink" class="hidden sponsor-link">http://www.pharmaphorum.com</span> <span id="ctl00_MainContent_ctl10_rptSponsors_ctl01_lblProfile" class="hidden sponsor-profile">pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl10_rptSponsors_ctl02_imgSponsor" class="sponsor-image" src="/_media/partners/4284.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl10_rptSponsors_ctl02_lblName" class="hidden sponsor-name">The Medicine Maker</span> <span id="ctl00_MainContent_ctl10_rptSponsors_ctl02_lblType" class="hidden sponsor-type">Supporters</span> <span id="ctl00_MainContent_ctl10_rptSponsors_ctl02_lblLink" class="hidden sponsor-link">https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo</span> <span id="ctl00_MainContent_ctl10_rptSponsors_ctl02_lblProfile" class="hidden sponsor-profile"> The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo </span> </div> </li> </ul> </div> </div> <div class="clearfix"></div> <div class="buttons buttons_ed" style="margin-bottom: 40px;"> <a id="ctl00_MainContent_ctl10_rptSponsors_ctl03_lnkPopup" class="button-white open-popup-link" href="#pop-supporters">view all Supporters</a> <a href="#pop-sponsor" class="button-white open-popup-link">Sponsor the conference</a> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_associatedevents"> <div class="associate_event_sec"> <h2 class="no_marg"></h2> <h5 class="no_marg"><p style="margin-top:20px">SAE Group Media is delighted to confirm that AI USA is now in association with RNA Therapeutics USA and together they form Drug Discovery Week.</p><p>What’s more, when you secure your ticket to AI USA and your colleague books for RNA USA, you will receive a <strong>50%* discount</strong> across both tickets – confirm your attendance to both events below!</p><p><strong><a href="#pop-attend-group" class="open-popup-link actv blue-button">50% Off Tickets</a></strong></p><p>*Please note: This offer is for new bookings only and cannot be used in conjunction with other offers. For full terms and conditions, <a href="/privacy-legals/terms-conditions/">click here</a></p></h5> <div id="conference-slider" class="slider"> <div class="event_Inner"> <div class="row"> <div class="col-sm-5"> <div class="event_Inner_Left"><a href="/pharmaceuticals/archive/10-2024/conference/"><img src="/eventImages/6086_overview.png?width=650&height=499&bgcolor=white&scale=canvas" alt="AI in Drug Discovery USA" /></a> </div> </div> <div class="col-sm-7"> <div class="event_Inner_Right"> <h3><a href="/pharmaceuticals/archive/10-2024/conference/">AI in Drug Discovery USA</a></h3> <p>Courtyard by Marriott Boston Downtown<br> 21 October - 22 October 2024<br> , USA</p> <ul> <li><a href="/pharmaceuticals/archive/10-2024/conference//booknow" class="actv blue-button">Register To Attend</a></li> <li><a href="/pharmaceuticals/archive/10-2024/conference/#tab_programme">View Programme</a></li> <li><a href="/pharmaceuticals/archive/10-2024/conference/">View Details</a></li> </ul> </div> </div> </div></div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_venue"> <div class="venue_sec"> <h2 class="font_weght">VENUE</h2> <h2 class="font_weght2">Courtyard by Marriott Boston Downtown</h2> <p>Boston, USA</p> <div class="row"> <div class="col-sm-6"> <div class="venue_left"> <a href="#"><img src="/documentPortal/venueImages/543.jpg" alt="" /></a> </div> </div> <div class="col-sm-6"> <div class="venue_map"> <iframe src="https://www.google.com/maps/embed?pb=!1m18!1m12!1m3!1d2948.6474661864363!2d-71.06803598940255!3d42.35003893561608!2m3!1f0!2f0!3f0!3m2!1i1024!2i768!4f13.1!3m3!1m2!1s0x89e37a76dd680fd1%3A0x60dbfa1ba0c06db2!2sCourtyard%20by%20Marriott%20Boston%20Downtown!5e0!3m2!1sen!2suk!4v1686738969046!5m2!1sen!2suk" width="600" height="450" style="border:0;" allowfullscreen="" loading="lazy" referrerpolicy="no-referrer-when-downgrade""></iframe> </div> </div> </div> <div class="row"> <div class="col-sm-12"> <div class="venue_details"> <p></p> <div style="text-align:left"> <strong>A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.</strong> </div> <a href="/documentPortal/hotelBookingForms/6086.pdf?v=1">HOTEL BOOKING FORM</a> </div> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_downloads"> <div id="downloads"> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl00_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5393"><img id="ctl00_MainContent_ctl15_rptDownloads_ctl00_imgDownload" src="/documentportal/ComplementaryContent/5393.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Video Speaker Interview - Jim Weterings</h4> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl00_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5393">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl01_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5288"><img id="ctl00_MainContent_ctl15_rptDownloads_ctl01_imgDownload" src="/documentportal/ComplementaryContent/5288.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Past Attendee List </h4> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl01_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5288">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl02_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5310"><img id="ctl00_MainContent_ctl15_rptDownloads_ctl02_imgDownload" src="/documentportal/ComplementaryContent/5310.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Brochure</h4> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl02_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5310">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl03_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5282"><img id="ctl00_MainContent_ctl15_rptDownloads_ctl03_imgDownload" src="/documentportal/ComplementaryContent/5282.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Speaker Interview - TRANSCODE THERAPEUTICS</h4> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl03_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5282">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl04_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5245"><img id="ctl00_MainContent_ctl15_rptDownloads_ctl04_imgDownload" src="/documentportal/ComplementaryContent/5245.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Past Presentation - HDT Bio</h4> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl04_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5245">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl05_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5244"><img id="ctl00_MainContent_ctl15_rptDownloads_ctl05_imgDownload" src="/documentportal/ComplementaryContent/5244.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Past Presentation - Avidity</h4> <a id="ctl00_MainContent_ctl15_rptDownloads_ctl05_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/northamerica/conference/rna-usa?o=login&dpb=1&dl=cc&p1=6053&p2=5244">Download</a> </div> </div> </div>  </div> </div> </div> </div> </div> </div> </div> <div> <div class="container"> <div class="row"> <div class="col-sm-12"> </div> </div> </div> </div> <div id="pop-exhibitors" class="white-popup mfp-hide"> <h3 style="padding-left: 0"> Exhibitors</h3> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.chemgenes.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/4103.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> ChemGenes</h3> <div class="subtitle"> Exhibitors</div> <a href="http://www.chemgenes.com" target="_blank" class="link" align="right"> http://www.chemgenes.com</a> <br /> <br /> <div class="textbody"> ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support. </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="https://www.trilinkbiotech.com/" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/5639.png" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> TriLink BioTechnologies</h3> <div class="subtitle"> Exhibitors</div> <a href="https://www.trilinkbiotech.com/" target="_blank" class="link" align="right"> https://www.trilinkbiotech.com/</a> <br /> <br /> <div class="textbody"> <p>TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.<p> </div> <br /> </div> </div> </div> <div id="pop-supporters" class="white-popup mfp-hide"> <h3 style="padding-left: 0"> Media Partners</h3> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/4284.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> The Medicine Maker</h3> <div class="subtitle"> Supporters</div> <a href="https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo" target="_blank" class="link" align="right"> https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo</a> <br /> <br /> <div class="textbody"> The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.pharmaphorum.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/2411.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> pharmaphorum</h3> <div class="subtitle"> Supporters</div> <a href="http://www.pharmaphorum.com" target="_blank" class="link" align="right"> http://www.pharmaphorum.com</a> <br /> <br /> <div class="textbody"> pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com </div> <br /> </div> </div> </div> <div id="pop-ical" class="ical-popup mfp-hide"> <h3 style="padding-left: 0px; margin: 0px"> SAVE TO</h3> <br /> <img src="/_images/newsite/cal-1.jpg" alt="Outlook Calendar" />  <a href="/pharmaceuticals/northamerica/conference/rna-usa/event.ics" style="color: #000">OUTLOOK CALENDAR</a><br /> <img src="/_images/newsite/cal-2.jpg" alt="Google Calendar" />  <a href="http://www.google.com/calendar/event?action=TEMPLATE&text=RNA+Therapeutics+USA&dates=20241023T070000Z/20241024T155000Z&details=SAE+Media+Group+is+proud+to+announce+the+2nd+annual+RNA+Therapeutics+USA+Conference+taking+place+in+Boston+on+the+23+%e2%80%93+24th+October+2024&location=Courtyard+by+Marriott+Boston+Downtown%2c+&sprop=website:www.smi-online.co.uk" style="color: #000">GOOGLE CALENDAR</a><br /> <img src="/_images/newsite/cal-3.jpg" alt="ICal Calendar" />  <a href="/pharmaceuticals/northamerica/conference/rna-usa/event.ics" style="color: #000">ICAL CALENDAR</a><br /> <img src="/_images/newsite/cal-4.jpg" alt="Yahoo! Calendar" />  <a href="http://calendar.yahoo.com/?v=60&TYPE=18&TITLE=RNA+Therapeutics+USA&ST=20241023T070000Z&ET=20241024T155000Z&in_loc=Courtyard+by+Marriott+Boston+Downtown%2c+&DESC=SAE+Media+Group+is+proud+to+announce+the+2nd+annual+RNA+Therapeutics+USA+Conference+taking+place+in+Boston+on+the+23+%e2%80%93+24th+October+2024" style="color: #000">YAHOO! CALENDAR</a><br /> </div> <div id="pop-venue" class="white-popup mfp-hide"> <h3 style="padding-left: 0px; margin: 0px"> Courtyard by Marriott Boston Downtown</h3> <br/> USA<br/> <br /> <div class="clearfix"> <div class="s-left-side" style="width: 50%; display: table-cell; vertical-align: top; float: left;"> <img src="/documentPortal/venueImages/543.jpg?width=350" alt="Courtyard by Marriott Boston Downtown" class="img-responsive" /> </div> <div class="s-right-side" style="width: 50%; display: table-cell; float: left; text-align: right"> <iframe class="iframe-map" style="height: 350px; width: 100%; padding-left: 10px; border: 0" src="https://www.google.com/maps/embed?pb=!1m18!1m12!1m3!1d2948.6474661864363!2d-71.06803598940255!3d42.35003893561608!2m3!1f0!2f0!3f0!3m2!1i1024!2i768!4f13.1!3m3!1m2!1s0x89e37a76dd680fd1%3A0x60dbfa1ba0c06db2!2sCourtyard%20by%20Marriott%20Boston%20Downtown!5e0!3m2!1sen!2suk!4v1686738969046!5m2!1sen!2suk" width="600" height="450" style="border:0;" allowfullscreen="" loading="lazy" referrerpolicy="no-referrer-when-downgrade"" frameborder="0"></iframe> </div> </div> <br /> <div style="margin-top:20px;"> <a href="/documentPortal/hotelBookingForms/6086.pdf" class="log_btn" target="_blank">HOTEL BOOKING FORM</a> </div> </div> <div id="pop-speaker-single" class="white-popup mfp-hide"> <br /> <div class="clearfix"> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0px; margin: 0px"> Title</h3> <span class="subtitle">SubTitle</span> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <img src="" alt="speaker image" class="img-responsive popup-image" align="right" /> </div> </div> <br /> <div class="textbody"> Content </div> </div> <div id="pop-media-single" class="white-popup mfp-hide"> <br /> <div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0; margin: 0"> </h3> <div class="subtitle"> </div> <a href="" target="_blank" class="link"> </a> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <a href="" target="_blank" class="imagelink"> <img src="" alt="sponsor image" class="img-responsive popup-image" align="right" /></a> </div> </div> <br /> <div class="textbody"> </div> </div> </div> <div id="pop-download" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> </div> <div id="pop-download-presentation" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> <a href="#pop-login" class="open-popup-link log_btn login_link">Login</a><br /> </div> <div id="pop-video" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <div class="video"><iframe class="if" src="" width="640" height="564" frameborder="0" allow="autoplay; fullscreen" allowfullscreen></iframe></div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> <a href="#pop-login" class="open-popup-link log_btn login_link">Login</a><br /> </div> <div class="container-fluid darkgrey"> <footer class="container"> <div class="contact-details"> <ul class="contact"> <li><a href="#pop-contact" class="open-popup-link">+44 (0)20 7827 6000</a></li> <li><a href="#pop-contact" class="open-popup-link">events@saemediagroup.com</a></li> </ul> <a href="#pop-cpd" class="open-popup-link"><img src="/_images/newsite/cpd.png" alt="" /></a> </div> <div class="participate"> <a href="#pop-speak" class="open-popup-link">Speak</a> <a href="#pop-sponsor" class="open-popup-link">Sponsor</a> <a href="#pop-attend" class="open-popup-link">Attend</a> <a href="/about-us/help">Help</a> <span> <a href="#pop-register" class="open-popup-link">Sign up</a>/<a href="#pop-login" class="open-popup-link">Login</a> </span> </div> <div> <ul class="nav navbar-nav"> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> </ul> </div> <div class="follow"> <p>follow us</p> <a href="http://www.linkedin.com/company/407332" class="linkedin" target="_blank"></a> <a href="https://twitter.com/SAEMGPharma" class="twitter" target="_blank"></a> </div> </footer> <hr /> <p class="copyright"> copyright © 2024 SAE Media Group</p> </div> <div id="cookie-use" class="cookie-use"> <div id="logo" class="cookie_img"> <a href="/"> <img alt="Home" src="/_images/newsite/logo.png" class="img-responsive" /></a> </div> <div class="cookie_content"> <h1> Cookie Policy</h1> <p> From May 2011 a new privacy law came into effect across the EU. The law requires that websites ask visitors for consent to use most web cookies. We use cookies to ensure you get the best experience on our website –Tick here to accept cookie use <input type="checkbox" id="cbAcceptCookieUse" /><br /> Details of our cookie use may be found <a href="/cookies">here</a>. </p> </div> </div> <script type="text/javascript"> //<![CDATA[ (function() {var fn = function() {$get("ctl00_ToolkitScriptManager1_HiddenField").value = '';Sys.Application.remove_init(fn);};Sys.Application.add_init(fn);})();//]]> </script> </form> <div id="pop-cpd" class="white-popup mfp-hide"> <img src="/_images/newsite/cpd-large.jpg"><br> <h3> WHAT IS CPD?</h3> <p> CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is: </p> <p> <i>‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’</i> </p> <p> CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities. </p> <p> Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld. </p> <p> CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading. </p> <h3> CPD AND PROFESSIONAL INSTITUTES</h3> <p> There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD. </p> <p> For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained. </p> <p> CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities. </p> <h3> TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)</h3> <p> Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based. </p> <p> <b>‘Input’</b> based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning. </p> <p> <b>‘Output’</b> based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning. </p> <p> The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently. </p> <p> As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements. </p> <h3> GLOBAL CPD</h3> <p> Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace. </p> <h3>CPD Certificates</h3> <p> We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email <a href="mailto:events@saemediagroup.com">events@saemediagroup.com</a> </p> </div> <div id="pop-news" class="white-popup mfp-hide"> <h3 class="news-evttitle" style="padding-left: 0px"> Event Title</h3> <h3 class="news-headline" style="padding-left: 0px"> Headline</h3> <div class="news-text"> Text </div> <a href="javascript:void(0)" class="news-evtlink log_btn" >Read More</a> </div> <div id="pop-speak" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>I would like to speak at an event</h3> <div class="register_sec"> <form id="speak_form" action="" method="post"> <div class="ctrl-grp"> <label class="title"> Which conference are you interested in speaking at?</label> <select id="speak_conf" name="speak_conf" class="register-select conf_group"> <option value="">Select ...</option><option value="6030">Counter UAS Technology USA </option><option value="6043">Energy From Waste</option><option value="6029">Military Airlift and Air-to-Air Refuelling</option><option value="6057">Pre-Filled Syringes and Injectable Drug Devices </option><option value="6061">Maritime Reconnaissance and Surveillance Technology</option><option value="6060">Mobile Deployable Communications</option><option value="6063">UAV Technology USA</option><option value="6064">Counter UAS Homeland Security USA</option><option value="6065">RNA Therapeutics </option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option> </select> </div> <div class="ctrl-grp"> <label class="title">Not listed above?</label> <input type="text" id="speak_notlisted" name="speak_notlisted" value="" class="form-control conf_group" spellcheck="false" /> </div> <div class="ctrl-grp"> <label class="title"> How can we help?</label> <textarea id="speak_help" name="speak_help" class="form-control"></textarea> </div> <div class="indent"> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="speak_org" name="speak_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Website</label> <input type="text" id="speak_website" name="speak_website" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Title</label>  <select id="speak_title" name="speak_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="speak_title_other" name="speak_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#speak_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#speak_title_other').prop('disabled', false); $('#speak_title_other').css({ 'background-color': '#fff' }); $('#speak_title_other').parent().slideDown(); } else { $('#speak_title_other').val(''); $('#speak_title_other').prop('disabled', true); $('#speak_title_other').css({ 'background-color': '#ccc' }); $('#speak_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="speak_firstname" name="speak_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="speak_surname" name="speak_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="speak_email" name="speak_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Phone*</label> <input type="text" id="speak_phone" name="speak_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="speak_add" name="speak_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <label class="title"> What is the topic you wish to speak about?</label> <textarea id="speak_topic" name="speak_topic" class="form-control"></textarea> </div> <div class="ctrl-grp checkbox-grp"> <div><input id="speak_returning" name="speak_returning" type="checkbox" /></div> <label for="speak_returning"> I'm a returning speaker from a previous event</label> </div> <div class="ctrl-grp"> <label class="title"> Where did you hear about SAE Media Group?</label> <input type="text" id="speak_hear" name="speak_hear" value="" class="form-control" /> </div> <input id="speak_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-attend-group" class="white-popup mfp-hide"></div> <div id="pop-attend" class="white-popup mfp-hide"> <div style="width: 100%"> <h3 id="popTitle">I would like to attend an event</h3> <h3 id="popGroupTitle">Group Booking</h3> <h4 id="popGroupSubTitle" style="padding-left:80px;">Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours</h4> <div class="register_sec"> <form id="attend_form" action="" method="post"> <div class="ctrl-grp" id="divAttendConf"> <label class="title">Which conference are you interested in attending?</label> <select id="attend_conf" name="attend_conf" class="register-select conf_group"> <option value="">Select ...</option><option value="6030">Counter UAS Technology USA </option><option value="6043">Energy From Waste</option><option value="6029">Military Airlift and Air-to-Air Refuelling</option><option value="6057">Pre-Filled Syringes and Injectable Drug Devices </option><option value="6061">Maritime Reconnaissance and Surveillance Technology</option><option value="6060">Mobile Deployable Communications</option><option value="6063">UAV Technology USA</option><option value="6064">Counter UAS Homeland Security USA</option><option value="6065">RNA Therapeutics </option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option> </select> </div>   <div class="indent"> <div class="ctrl-grp" id="divGroupSize"> <label>Group size</label> <input type="text" id="attend_groupSize" name="attend_groupSize" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="attend_org" name="attend_org" value="" class="form-control" spellcheck="false" /> </div>  <div class="ctrl-grp"> <label>Title</label>  <select id="attend_title" name="attend_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="attend_title_other" name="attend_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#attend_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#attend_title_other').prop('disabled', false); $('#attend_title_other').css({ 'background-color': '#fff' }); $('#attend_title_other').parent().slideDown(); } else { $('#attend_title_other').val(''); $('#attend_title_other').prop('disabled', true); $('#attend_title_other').css({ 'background-color': '#ccc' }); $('#attend_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="attend_firstname" name="attend_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="attend_surname" name="attend_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="attend_email" name="attend_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Phone*</label> <input type="text" id="attend_phone" name="attend_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="attend_add" name="attend_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp checkbox-grp" id="divAttendReturning"> <div><input id="attend_returning" name="attend_returning" type="checkbox" /></div> <label for="attend_returning">I'm a returning attendee from a previous event</label> </div>  <input id="attend_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-sponsor" class="white-popup mfp-hide"> <div style="width: 100%"> <h3 id="hSponsorExhibit">I would like to sponsor/exhibit at an event</h3> <div class="register_sec"> <form id="sponsor_form" action="" method="post"> <div class="ctrl-grp" id="divWhichConf"> <label class="title">Which conference are you interested in sponsoring?</label> <select id="sponsor_conf" name="sponsor_conf" class="conf_group"> <option value="">Select ...</option><option value="6030">Counter UAS Technology USA </option><option value="6043">Energy From Waste</option><option value="6029">Military Airlift and Air-to-Air Refuelling</option><option value="6057">Pre-Filled Syringes and Injectable Drug Devices </option><option value="6061">Maritime Reconnaissance and Surveillance Technology</option><option value="6060">Mobile Deployable Communications</option><option value="6063">UAV Technology USA</option><option value="6064">Counter UAS Homeland Security USA</option><option value="6065">RNA Therapeutics </option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option> </select> </div> <div class="ctrl-grp" id="divNotListed"> <label class="title">Not listed above?</label> <input id="sponsor_notlisted" name="sponsor_notlisted" type="text" value="" class="form-control conf_group" spellcheck="false" /> </div> <div class="ctrl-grp hidden"> <label class="title"> What type of sponsorship are you interested in?</label> <ul class="checkbox-list"> <li> <input id="sponsor_lead" name="sponsor_lead" type="checkbox" /> <label for="sponsor_lead">Lead Sponsor</label> </li> <li> <input id="sponsor_speaking" name="sponsor_speaking" type="checkbox" /> <label for="sponsor_speaking">Speaking</label> </li> <li> <input id="sponsor_exhibit" name="sponsor_exhibit" type="checkbox" /> <label for="sponsor_exhibit">Exhibit</label> </li> <li> <input id="sponsor_networking" name="sponsor_networking" type="checkbox" /> <label for="sponsor_networking">Networking Reception Sponsor</label> </li> <li> <input id="sponsor_coffee" name="sponsor_coffee" type="checkbox" /> <label for="sponsor_coffee">Coffee/Tea Break Sponsor</label> </li> <li> <input id="sponsor_lunch" name="sponsor_lunch" type="checkbox" /> <label for="sponsor_lunch">Lunch Sponsor</label> </li> <li> <input id="sponsor_branding" name="sponsor_branding" type="checkbox" /> <label for="sponsor_branding">Branding Package</label> </li> <li> <input id="sponsor_lanyards" name="sponsor_lanyards" type="checkbox" /> <label for="sponsor_lanyards">Lanyards Sponsor</label> </li> </ul> </div> <div class="indent"> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="sponsor_org" name="sponsor_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp hidden"> <label>Website</label> <input type="text" id="sponsor_website" name="sponsor_website" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Job Title*</label> <input type="text" id="sponsor_jobtitle" name="sponsor_jobtitle" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Title</label>  <select id="sponsorVar_title" name="sponsorVar_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="sponsor_title_other" name="sponsor_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#sponsorVar_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#sponsor_title_other').prop('disabled', false); $('#sponsor_title_other').css({ 'background-color': '#fff' }); $('#sponsor_title_other').parent().slideDown(); } else { $('#sponsor_title_other').val(''); $('#sponsor_title_other').prop('disabled', true); $('#sponsor_title_other').css({ 'background-color': '#ccc' }); $('#sponsor_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="sponsor_firstname" name="sponsor_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="sponsor_surname" name="sponsor_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="sponsor_email" name="sponsor_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Phone*</label> <input type="text" id="sponsor_phone" name="sponsor_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="sponsor_add" name="sponsor_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp hidden"> <label class="title">What are your sponsorship goals?</label> <textarea id="sponsor_goals" name="sponsor_goals" class="form-control"></textarea> </div> <div class="ctrl-grp checkbox-grp hidden"> <div><input id="sponsor_returning" name="sponsor_returning" type="checkbox" value="true"></div> <label for="sponsor_returning">I'm a returning sponsor from a previous event</label> </div> <div class="ctrl-grp hidden"> <label class="title">Where did you hear about SAE Media Group?</label> <input id="sponsor_hear" name="sponsor_hear" type="text" value="" class="form-control" /> </div> <input id="sponsor_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-login" class="white-popup mfp-hide"> <div style="width: 100%"> <h3> SIGN UP OR LOGIN</h3> <div class="register_sec"> <div class="sign_linkd hidden"> <a href="javascript:void(0)">SIGN UP/LOG IN with linked in</a> </div> <form id="login_form" action="" method="post"> <input id="login_reload" type="hidden" value="" /> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="login_email" name="login_email" type="text" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> PASSWORD*</label> <input id="login_password" name="login_password" type="password" value="" class="form-control" autocomplete="off" /> </div> </div> <div class="ctrl-grp checkbox-grp"> <input id="login_rememberme" name="login_rememberme" type="checkbox" /> <label for="login_rememberme"> Keep me signed in</label> </div> <div> <a href="#pop-register" id="sign_btn_link" class="open-popup-link sign_btn">Sign up</a> <input id="login_button" type="submit" value="Log In" class="log_btn" /> </div> <div style="margin-top: 20px;"> <a href="#pop-forgot" class="open-popup-link">Forgotten Password?</a> </div> </form> <div id="login_failed" style="display: none"> <p> Sorry, the login details you entered were not found. Please try again. Alternatively you may register a new account <a href="#pop-register" class="open-popup-link">here</a>. </p> <p> Accounts are locked after <span id="ctl00_popupLogin_maxAttempts">5</span> failed attempts.</p> </div> </div> </div> </div> <div id="pop-register" class="white-popup mfp-hide"> <div style="width: 100%"> <center> <img src="/_images/newsite/logo.png" style="text-align: center" /></center> <div class="register_sec"> <form id="register_form" action="" method="post"> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="register_email" name="register_email" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> PASSWORD*</label> <input id="register_password" name="register_password" type="password" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> CONFIRM*</label> <input id="register_confirm" name="register_confirm" type="password" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label>TITLE*</label>  <select id="register_title" name="register_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="register_title_other" name="register_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#register_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#register_title_other').prop('disabled', false); $('#register_title_other').css({ 'background-color': '#fff' }); $('#register_title_other').parent().slideDown(); } else { $('#register_title_other').val(''); $('#register_title_other').prop('disabled', true); $('#register_title_other').css({ 'background-color': '#ccc' }); $('#register_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label> FIRST NAME*</label> <input id="register_firstname" name="register_firstname" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> SURNAME*</label> <input id="register_surname" name="register_surname" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> COUNTRY*</label> <select id="register_country" name="register_country" class="register-select"> <option value="">Select ...</option><option value="222">United Kingdom</option><option value="223">USA</option><option value="85">Germany</option><option value="78">France</option><option value="108">Italy</option><option value="102">India</option><option value="154">Netherlands</option><option value="205">Switzerland</option><option value="26">Belgium</option><option value="">------------------------------</option><option value="1">Afghanistan</option><option value="2">Albania</option><option value="3">Algeria</option><option value="4">American Samoa</option><option value="5">Andorra</option><option value="6">Angola</option><option value="7">Anguilla</option><option value="8">Antarctica-Casey</option><option value="9">Antarctica-Scott</option><option value="10">Antigua and Barbuda</option><option value="11">Argentina</option><option value="12">Armenia</option><option value="13">Aruba</option><option value="14">Ascension Islands</option><option value="15">Ashmore & Cartier Islands</option><option value="16">Atlantic East</option><option value="17">Atlantic West</option><option value="18">Australia</option><option value="19">Austria</option><option value="20">Azerbaijan</option><option value="21">Bahamas</option><option value="22">Bahrain</option><option value="23">Bangladesh</option><option value="24">Barbados</option><option value="25">Belarus</option><option value="27">Belize</option><option value="28">Benin</option><option value="29">Bermuda</option><option value="30">Bhutan</option><option value="31">Bolivia</option><option value="32">Bosnia and Herzegovina</option><option value="33">Botswana</option><option value="34">Brazil</option><option value="36">Brunei Darussalam</option><option value="37">Bulgaria</option><option value="38">Burkina Faso</option><option value="39">Burma</option><option value="40">Burundi</option><option value="41">Cambodia</option><option value="42">Cameroon</option><option value="43">Canada</option><option value="240">Canary Islands</option><option value="44">Cape Verde</option><option value="45">Cayman Islands</option><option value="46">Central African Republic</option><option value="47">Chad</option><option value="48">Chile</option><option value="49">China</option><option value="50">Christmas Island</option><option value="51">Clipperton Island</option><option value="52">Cocos (Keeling) Islands</option><option value="53">Colombia</option><option value="54">Comoros</option><option value="55">Congo</option><option value="56">Cook Islands</option><option value="57">Costa Rica</option><option value="58">Croatia</option><option value="59">Cuba</option><option value="60">Cyprus</option><option value="61">Czech Republic</option><option value="62">Denmark</option><option value="63">Djibouti</option><option value="64">Dominica</option><option value="65">Dominican Republic</option><option value="241">Easter Island</option><option value="67">Ecuador</option><option value="68">Egypt</option><option value="69">El Salvador</option><option value="70">Equatorial Guinea</option><option value="71">Eritrea</option><option value="72">Estonia</option><option value="73">Ethiopia</option><option value="254">Europe</option><option value="74">Falkland Islands</option><option value="75">Faroe Islands</option><option value="76">Fiji</option><option value="77">Finland</option><option value="79">French Guiana</option><option value="80">French Polynesia</option><option value="81">Gabon</option><option value="242">Galapagos Islands</option><option value="82">Gambia</option><option value="83">Gaza Strip</option><option value="84">Georgia</option><option value="86">Ghana</option><option value="87">Gibraltar</option><option value="88">Greece</option><option value="89">Greenland</option><option value="90">Grenada</option><option value="91">Guadeloupe</option><option value="92">Guam</option><option value="93">Guatemala</option><option value="94">Guinea</option><option value="95">Guinea-Bissau</option><option value="96">Guyana</option><option value="97">Haiti</option><option value="252">Hawaii</option><option value="98">Honduras</option><option value="99">Hong Kong</option><option value="100">Hungary</option><option value="101">Iceland</option><option value="103">Indonesia</option><option value="104">Iran, Islamic Republic of</option><option value="105">Iraq</option><option value="106">Ireland</option><option value="107">Israel</option><option value="110">Ivory Coast</option><option value="111">Jamaica</option><option value="112">Japan</option><option value="113">Jordan</option><option value="114">Kazakhstan</option><option value="115">Kenya</option><option value="116">Kiribati</option><option value="119">Kuwait</option><option value="120">Kyrgyzstan</option><option value="121">Laos</option><option value="122">Latvia</option><option value="123">Lebanon</option><option value="124">Lesotho</option><option value="125">Liberia</option><option value="126">Libya</option><option value="127">Liechtenstein</option><option value="128">Lithuania</option><option value="129">Luxembourg</option><option value="130">Macau</option><option value="131">Macedonia</option><option value="132">Madagascar</option><option value="133">Malawi</option><option value="134">Malaysia</option><option value="135">Maldives</option><option value="136">Mali</option><option value="137">Malta</option><option value="163">Marianas Islands</option><option value="138">Marshall Islands</option><option value="139">Martinique</option><option value="140">Mauritania</option><option value="141">Mauritius</option><option value="142">Mayotte Islands</option><option value="143">Mexico</option><option value="144">Micronesia</option><option value="145">Moldova</option><option value="146">Monaco</option><option value="147">Mongolia</option><option value="244">Montenegro</option><option value="148">Montserrat</option><option value="149">Morocco</option><option value="150">Mozambique</option><option value="245">Myanmar</option><option value="151">Namibia</option><option value="152">Nauru</option><option value="153">Nepal</option><option value="155">Netherlands Antilles</option><option value="156">New Caledonia</option><option value="157">New Zealand</option><option value="158">Nicaragua</option><option value="159">Niger</option><option value="160">Nigeria</option><option value="161">Niue</option><option value="255">None</option><option value="162">Norfolk Island</option><option value="117">North Korea</option><option value="164">Norway</option><option value="165">Oman</option><option value="166">Pakistan</option><option value="167">Palau</option><option value="251">Palestine</option><option value="168">Panama</option><option value="169">Papua New Guinea</option><option value="170">Paraguay</option><option value="171">Peru</option><option value="172">Philippines</option><option value="173">Poland</option><option value="174">Portugal</option><option value="175">Puerto Rico</option><option value="176">Qatar</option><option value="177">Réunion</option><option value="178">Romania</option><option value="179">Russia</option><option value="180">Rwanda</option><option value="181">Saint Helena</option><option value="182">Saint Kitts and Nevis</option><option value="183">Saint Lucia</option><option value="184">Saint Vincent/Grenadines</option><option value="185">Samoa</option><option value="186">San Marino</option><option value="187">Sao Tome</option><option value="188">Saudi Arabia</option><option value="253">Scotland</option><option value="189">Senegal</option><option value="246">Serbia</option><option value="190">Seychelles</option><option value="191">Sierra Leone</option><option value="192">Singapore</option><option value="193">Slovakia</option><option value="194">Slovenia</option><option value="195">Solomon Islands</option><option value="196">Somalia</option><option value="197">Somoa Western</option><option value="198">South Africa</option><option value="118">South Korea</option><option value="199">Spain</option><option value="200">Sri Lanka</option><option value="201">Sudan</option><option value="202">Suriname</option><option value="203">Swaziland</option><option value="204">Sweden</option><option value="206">Syria</option><option value="247">Tahiti</option><option value="207">Taiwan</option><option value="208">Tajikistan</option><option value="209">Tanzania</option><option value="248">Tatarstan</option><option value="256">TBC</option><option value="210">Thailand</option><option value="211">Togo</option><option value="212">Tonga</option><option value="213">Trinidad and Tobago</option><option value="214">Tunisia</option><option value="215">Turkey</option><option value="216">Turkmenistan</option><option value="217">Turks and Caicos Islands</option><option value="218">Tuvalu</option><option value="219">Uganda</option><option value="220">Ukraine</option><option value="221">United Arab Emirates</option><option value="224">Uruguay</option><option value="225">Uzbekistan</option><option value="249">Vanatu</option><option value="226">Vanuatu</option><option value="227">Vatican City (Holy See)</option><option value="228">Venezuela</option><option value="229">Vietnam</option><option value="35">Virgin Islands, British</option><option value="230">Virgin Islands, U.S.</option><option value="231">Wallis And Futuna</option><option value="232">West Bank</option><option value="250">West Indies</option><option value="233">Western Sahara</option><option value="234">Yemen</option><option value="235">Yugoslavia</option><option value="236">Zaire</option><option value="237">Zambia</option><option value="238">Zimbabwe</option> </select> </div> <div class="ctrl-grp"> <label> ORGANISATION*</label> <input id="register_org" name="register_org" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> JOB TITLE*</label> <input id="register_jobtitle" name="register_jobtitle" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> PHONE*</label> <input id="register_phone" name="register_phone" type="text" value="" class="form-control" /> </div> </div> <div class="ctrl-grp checkbox-grp"> <div><input id="register_subscribe" name="register_subscribe" type="checkbox" /></div> <label for="register_subscribe"> I would like to receive information about other SAE Media Group products and services</label> </div> <div class="ctrl-grp checkbox-grp"> <div> <input id="register_rememberme" name="register_rememberme" type="checkbox" /></div> <label for="register_rememberme"> Keep me logged in</label> </div> <div class="ctrl-grp checkbox-grp"> <div> <input id="register_terms" name="register_terms" type="checkbox" /></div> <label for="register_terms"> * I have read and understood the full Terms of Use (please click <a href="/privacy-legals/terms-of-use" target="_blank">here</a> to see full Terms of Use - please note these will open in a new window). These Terms and Conditions are governed by English law.</label> </div> <input id="register_signup" type="submit" value="Sign up" class="log_btn" /> </form> <label id="register_error" class="error" style="display: none"> </label> </div> </div> </div> <div id="pop-contact" class="white-popup mfp-hide"> <div style="col-md-6"> <h3> Contact SAE Media Group</h3> <div class="register_sec"> <span style="color: #08478c">UK Office</span><br /> Opening Hours: 9.00 - 17.30 (local time)<br /> SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom<br /> Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001<br /> Website: <a href="https://www.smgconferences.com/" style="color: #08478c">http://www.smgconferences.com</a> Email: <a href="mailto:events@saemediagroup.com" style="color: #08478c">events@saemediagroup.com</a><br /> Registered in England - SMi Group Ltd trading as SAE Media Group<br /> <br /> <form id="contact_form" action="" method="post"> <div class="ctrl-grp"> <label class="title"> Nature of your enquiry</label><br /> <select id="contact_enquirytype" name="contact_enquirytype" class="register-select conf_group" style="width: 88%;"> <option value="0">I have an enquiry that is not listed below</option><option value="1">I am an existing delegate on a Conference/Workshop</option><option value="2">I have a general Conference/Executive Briefing query</option><option value="3">I am interested in attending an SAE Media Group Conference as a delegate</option><option value="4">I am interested in attending an SAE Media Group Workshop/Executive Briefing as a delegate</option><option value="5">I am interested in attending an SAE Media Group Masterclass as a delegate</option><option value="6">I am interested in speaking at an SAE Media Group event</option><option value="7">I am interested in sponsoring/exhibiting at an SAE Media Group event</option><option value="8">I am interested in marketing opportunities with SAE Media Group</option><option value="9">I am interested in employment opportunities SAE Media Group</option><option value="10">I would like to suggest a Conference topic</option><option value="11">I would like to suggest a Workshop/Executive Briefing topic</option><option value="12">I would like to suggest a Masterclass topic</option><option value="13">I have a technical query regarding this web site</option><option value="15">SAE Media Group Event Communities Related</option><option value="17">Sponsor Webinars</option><option value="14">Other</option> </select> </div> <div class="indent"> <div class="ctrl-grp"> <label> Name*</label> <input type="text" id="contact_name" name="contact_name" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Job Title*</label> <input type="text" id="contact_jobtitle" name="contact_jobtitle" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Organisation*</label> <input type="text" id="contact_org" name="contact_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Phone*</label> <input type="text" id="contact_phone" name="contact_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Email*</label> <input type="text" id="contact_email" name="contact_email" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <label class="title"> Enquiry*</label> <textarea class="form-control" id="contact_enquiry" name="contact_enquiry"></textarea> </div> <input type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-sponsor-single" class="white-popup mfp-hide"> <br /> <div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0; margin: 0"> </h3> <div class="subtitle"> </div> <a href="" target="_blank" class="link"> </a> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <a href="" target="_blank" class="imagelink"> <img src="" alt="sponsor image" class="img-responsive popup-image" align="right" /></a> </div> </div> <br /> <div class="textbody"> </div> </div> </div> <div id="pop-forgot" class="white-popup mfp-hide"> <div style="width: 100%"> <h3> Forgotten Password</h3> <div class="register_sec"> <form id="forgot_form" action="" method="post"> <span>Please enter the email address you registered with. We will email you a new password.</span> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="login_email" name="login_email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <input id="forgot_button" type="submit" value="Reset Password" class="log_btn" /> </form> <div id="reset_successful" style="display:none;"> <div>You have been sent an email with your new password. When you have recieved this email please continue to logon. Thank you.</div> <a href="#pop-login" class="open-popup-link log_btn">Continue</a> </div> <div id="reset_failed" style="display:none;"> <div>Sorry, we could not reset your password. Have you entered the correct email address?</div> </div> </div> </div> </div> <div id="pop-GDPRConsent" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>Thank you for visiting our event</h3> <div class="register_sec"> <form id="GDPRConsent_form" action="" method="post"> <input id="GDPRConsent_eventid" name="GDPRConsent_eventid" type="hidden" value="" /> <div class="ctrl-grp"> <h4>If you would like to receive further information about our events, please fill out the information below.</h4> </div> <div class="ctrl-grp"> <div style="float: left;margin-top:10px;"> <label>I am happy to receive information about SAE Media Group events by email:</label> </div> <div style="float: left;"> <input id="GDPRConsent_confirm" name="GDPRConsent_confirm" type="checkbox" value="" class="form-control" style="margin-left:20px;" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your email address:</label> <input id="GDPRConsent_email" name="GDPRConsent_email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your name:</label> <input id="GDPRConsent_name" name="GDPRConsent_name" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your phone number:</label> <input id="GDPRConsent_phone" name="GDPRConsent_phone" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div> <input id="GDPRConsent_button" type="submit" value="Submit" class="log_btn" /> </div> <div style="margin-top: 20px;"> By ticking above you are consenting to receive information by email from SAE Media Group.<br /> Full details of our privacy policy can be found here <a class="open-popup-link" href="https://www.smgconferences.com/privacy-legals/privacy-policy/">https://www.smgconferences.com/privacy-legals/privacy-policy/</a>.<br /> Should you wish to update your contact preferences at any time you can contact us at <a class="open-popup-link" href="mailto:data.privacy@smgconferences.com">data.privacy@smgconferences.com</a>.<br /> Should you wish to be removed from any future mailing lists please click on the following link <a class="open-popup-link" href="http://www.smgconferences.com/opt-out">http://www.smgconferences.com/opt-out</a> </div> </form> <div id="GDPRConsent_failed" style="display: none"> <p> Sorry, the login details you entered were not found. Please try again. Alternatively you may register a new account <a href="#pop-register" class="open-popup-link">here</a>. </p> </div> </div> </div> </div> <form></form> <div id="pop-DownloadBrochure" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>Fill in your details to download the brochure</h3> <div class="register_sec"> <form id="DownloadBrochure_Form" action="" method="post"> <input id="DownloadBrochure_EventID" name="DownloadBrochure_EventID" type="hidden" value="" /> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">First Name</label> <input id="DownloadBrochure_FirstName" name="DownloadBrochure_FirstName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Last Name</label> <input id="DownloadBrochure_LastName" name="DownloadBrochure_LastName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Email Address*</label> <input id="DownloadBrochure_Email" name="DownloadBrochure_Email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Company Name*</label> <input id="DownloadBrochure_CompanyName" name="DownloadBrochure_CompanyName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Telephone Number*</label> <input id="DownloadBrochure_TelephoneNumber" name="DownloadBrochure_TelephoneNumber" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <div style="float: left;"> <input id="DownloadBrochure_Confirm" name="DownloadBrochure_Confirm" type="checkbox" value="" class="form-control hidden" style="margin-left:20px;" checked /> </div> </div> <div> <input id="DownloadBrochure_Button" type="submit" value="Submit" class="log_btn" /> </div> <div style="margin-top:20px; font-weight:500;"> By submitting this form you agree to our <a href="/privacy-legals/privacy-policy/">privacy policy</a> and consent to receiving communications, you may opt out at any time. </div> <div class="hidden" style="margin-top: 20px;"> By ticking above you are consenting to receive information by email from SAE Media Group.<br /> Full details of our privacy policy can be found here <a class="open-popup-link" href="https://www.smgconferences.com/privacy-legals/privacy-policy/">https://www.smgconferences.com/privacy-legals/privacy-policy/</a>.<br /> Should you wish to update your contact preferences at any time you can contact us at <a class="open-popup-link" href="mailto:data@smgconferences.com">data@smgconferences.com</a>.<br /> Should you wish to be removed from any future mailing lists please click on the following link <a class="open-popup-link" href="http://www.smgconferences.com/opt-out">http://www.smgconferences.com/opt-out</a> </div> </form> </div> </div> </div> <script type="text/javascript"> _linkedin_partner_id = "1595001"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script><script type="text/javascript"> (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); </script> <noscript> <img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1595001&fmt=gif" /> </noscript> <script> (function(ss,ex){ window.ldfdr=window.ldfdr||function(){(ldfdr._q=ldfdr._q||[]).push([].slice.call(arguments));}; (function(d,s){ fs=d.getElementsByTagName(s)[0]; function ce(src){ var cs=d.createElement(s); cs.src=src; cs.async=1; fs.parentNode.insertBefore(cs,fs); }; ce('https://sc.lfeeder.com/lftracker_v1_'+ss+(ex?'_'+ex:'')+'.js'); })(document,'script'); })('p1e024BvLJX4GB6d'); </script> </body> </html>

CINXE.COM

RNA Therapeutics USA : Pharmaceuticals : North America